Cover Page  for Protocol  
 
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN9068 -4228 
Official title of study:  A 104 week clinical trial comparing long term glycaemic 
control of insulin degludec/liraglutide (IDegLira) versus 
insulin glargine  therapy in subjects with type 2 diabetes 
mellitus  (DUAL™ VIII)  
Document date:  [ADDRESS_664733] of contents
Protocol ...............................................................................................................................................
Appendix A .........................................................................................................................................
Appendix B ..........................................................................................................................................
Attachment I and II ............................................................................................................................
Protocol amendment 1 -MX.............................................................................................................
Protocol amendment 2 -NO..............................................................................................................
Protocol amendment 3 -Global/HQ .................................................................................................
Protocol amendment 4 -Global/HQ .................................................................................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:IDegLira
Trial ID: NN9068-4228
Clinical Trial Report
Appendix 16.1.101 March 2019
1.0
Final
16.1.1 Protocol and protocol amendments
CONFIDENTIAL
 
 
 
 
 
Redacted protocol  
Includes redaction of personal identifiable information only.  
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 1of 95
Protocol
Trial ID: NN9068 -4228
DUALTMVIII –Durability
A 104 week clinical trial comparing long term glycaemic control 
of insulin degludec/liraglutide (IDegLira) versus insulin glargine 
therapy i n subjects with type 2 diabetes mellitus
Trial phase: 3b
Protocol originator
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 2of [ADDRESS_664734] of abbreviations .........................................................................................................................................6
1Summary ....................................................................................................................................................8
2Flow chart ................................................................................................................................................11
3Background inf ormation and rationale for the trial ............................................................................15
3.1 Background information ..............................................................................................................15
3.2 Rationale for the trial ...................................................................................................................16
4Objectives and endpoints ........................................................................................................................17
4.1 Objectives ....................................................................................................................................17
4.2 Endpoints .....................................................................................................................................17
4.2.1 Primary endpoint ........................................................................................................17
4.2.2 Secondary endpoints ..................................................................................................17
[IP_ADDRESS] Supportive secondary endpoints ..........................................................[ADDRESS_664735] replacement .....................................................................................................................26
6.7 Rationale for trial population .......................................................................................................26
7Milestones .................................................................................................................................................27
8Methods and assessments .......................................................................................................................28
8.1 Visit procedures ...........................................................................................................................28
8.1.1 Fasting requirements ..................................................................................................28
8.1.2 Screening (visit 1) ......................................................................................................28
8.1.3 Randomisation (visit 2) ..............................................................................................29
8.1.4 Treatment initiation and titration ...............................................................................30
8.1.5 Diaries ........................................................................................................................31
8.1.6 Follow up visits (visit 14 and 15) ..............................................................................[ADDRESS_664736] related information ..........................................................................................................34
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 3of 95
8.2.1 Concomitant illness and medical history ...................................................................34
8.2.2 Concomitant medication ............................................................................................35
8.2.3 Smoking status (Tobacco use) ...................................................................................[ADDRESS_664737] compliance ......................................................................................................................45
9Tria l supplies ...........................................................................................................................................46
9.1 Trial products ...............................................................................................................................46
9.2 Labelling ......................................................................................................................................46
9.3 Storage .........................................................................................................................................47
9.4 Drug accountability and destruction ............................................................................................47
9.5 Auxiliary supplies ........................................................................................................................47
10Interactive web response system ............................................................................................................48
11Randomisation procedure and breaking of blinded codes ..................................................................48
12Adverse events, and technical complaints and pregnancies ................................................................49
12.1 Definitions ...................................................................................................................................49
12.2 Reporting of adverse events .........................................................................................................53
12.3 Follow -up of adverse events ........................................................................................................55
12.4 Technical complaints and technical complaint samples ..............................................................56
12.4.1 Reporting of technical complaints .............................................................................56
12.4.2 Collection, storage and shipment of technical complaint samples ............................57
12.5 Pregnancies ..................................................................................................................................57
12.5.1 Pregnancies in female subjects ..................................................................................57
12.5.2 Pregnancies in female partners of male subjects (only applicable for US) ................58
12.6 Precautions and/or overdose ........................................................................................................59
12.7 Committees related to safety ........................................................................................................60
12.7.1 Novo Nordisk safety committee ................................................................................60
12.7.2 Event adjudication committee ....................................................................................60
13Case report forms ....................................................................................................................................62
13.1 Corrections to case report forms ..................................................................................................62
13.2 Case report form flow ..................................................................................................................62
14Monitoring procedures ...........................................................................................................................64
15Data management ....................................................................................................................................65
16Computerised systems .............................................................................................................................65
17 S tatistical considerations ........................................................................................................................66
17.1 Sample size calculation ................................................................................................................67
17.2 Definition of analysis sets ............................................................................................................68
17.3 Primary endpoint ..........................................................................................................................69
17.4 Secondary endpoints ....................................................................................................................70
17.4.1 Supportive secondary endpoints ................................................................................70
[IP_ADDRESS] Efficacy endpoints ...............................................................................70
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 4of 95
[IP_ADDRESS] Safety endpoints ..................................................................................[ADDRESS_664738] during trial ...............................................................................................83
18.5 Premature termination of the trial and/or trial site .......................................................................83
19Protocol compliance ................................................................................................................................84
20Audits and inspections ............................................................................................................................84
21Critical documents ..................................................................................................................................85
22Responsibilities ........................................................................................................................................87
23Reports and publications ........................................................................................................................88
23.1 Communication of results ............................................................................................................88
23.1.1 Authorship .................................................................................................................89
23.1.2 Site-specific publications by [CONTACT_431] ................................
.................................89
23.2 Investigator access to data and review of results .........................................................................89
24Retention of clinical trial documentation ..............................................................................................90
25Institutional Review Boards/Independent Ethics Committees and regulatory authorities ..............91
26Indemnity statement ...............................................................................................................................92
27References ................................................................................................................................................93
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 5of 95
Appendices and attachments to the protocol
Attachment I :Global l ist of key  staff and relevant departments and suppliers of clinical 
relevance
Attachment II :Country  list of key  staff and relevant departments
Appendix A:Medical events of special interest, events with additional data collection and 
events requiring adjudication 
Appendix B:Monitoring of Calcitonin
Table of Figures
Page
Figure 5–1 Trial design .............................................................................................................................20
Figure 12–1 Initial reporting of AEs ...........................................................................................................54
Figure 17–1 Novo Nordisk classification of hypoglycaemia ......................................................................76
Figure 17–2 ADA classification of hypoglycaemia ....................................................................................77
Table of Tables
Page
Table 8–1 Twice weekly titration algorithm for trial products ................................................................31
Table 9–1 Investigational medicina l products .........................................................................................46
Table 9–2 Storage conditions for investigational medicinal products .....................................................47
Table 17–1 Power for varying treatment differences ................................................................................68
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 6of [ADDRESS_664739] of abbr eviations
ABPI[INVESTIGATOR_513372] -up
ADA American Diabetes Association GCP Good Clinical Practice
AE adverse event GLP-1 Glucagon -like peptide-1
ALAT Alanine aminotransferase HbA 1c glycosylated haemoglobin
ASAT aspartate aminotransferase hCG human Chorionic Gonadotropin
BG blood glucose HDL High densit y lipoprotein
BMI body  mass index IB Investigator’s Brochure
CKD -
EPI[INVESTIGATOR_513373]. Guideline for 
Good Clinical Practice 
CRF case report form IDeg insulin degludec
CTR clinical trial report IDegLira insulin degludec/liraglutide
DPP-4 Dipeptidy l peptidase-4 IDMSisotope -dilution mass 
spectrometry  
DUN dispensing unit number IGlar insulin glargine
EAC Event Adjudication Committee IRB/IECInstitutional Review 
Boards/Independent Ethics 
Committees and regulatory
EASDEuropean Association for the 
Study  of Diabetes IWRS interactive web response sy stem
ECG Electrocardiogram LDL Low-densit y lipoprotein
eCRF electronic case report form LLOQ lower limit of quantification
EOT end of treatment LSFV Last subjects first visit
FAS full analy sis set MACEmajor adverse cardiovascular 
events
FDAU.S. Food and Drug 
AdministrationMESI medical event of special interest
FPG fasting plasma glucose MI myocardial infarction
FSFV first subject first visit MMRMmixed model for repeated 
measurement
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 7of [ADDRESS_664740]
QD quaque die (once dail y)
SAE serious adverse event
SAS safet y analysis set
s.c. Subcutaneous
SF-36v2Medical outcomes stud y 36-
item short form version [ADDRESS_664741] 
measure
TSH thyroid stimulating hormone
UTN Universal Trial Number
VLDL very-low-density  lipoprotein
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 8of 95
1 Summary
Primary objective
To compare long -term glycaemic control of insulin degludec/liraglutide (IDegL ira) versus insulin 
glargine ( IGlar )in insulin naïve subjects with ty pe 2 diabete s mel litus ( T2DM )inadequately  
controlled on oral antidiabetic drugs ( OAD [s]).
The secondary objective
To compare long -term efficacy  and safety  of IDegLira versus IGlar in insulin naïve subjects with 
T2DM inadequatel y controlled with OAD(s) .
Primary endpoint
The following endpoint will be assessed up to 104 weeks. Time from randomisation to inadequate 
glycaemic control and need for treatmen t intensification, defined as a glycosylated 
haemoglobin
(HbA 1c) of ≥7.0% at 2 consecutive visits from week 26 , including week 26 if HbA 1c was ≥ 7% at 
week 12 .
Key s upportive secondary efficacy endpoints
Time from randomisation to an HbA 1c˃6.5% at 2 consecutive visits from week 26
Chang e from base line after 26 weeks of treatment in:
oHbA 1c
obody  weight
oFasting plasma glucose (FPG)
o9-point Self-measured plasma glucose (SMPG) profile (individual points in the profile)
Insulin dose afte r 26 weeks of treatment
Responder after 26 and 104 weeks of treatment (yes/no):
oHbA 1c<
7.0%
oHbA 1c≤ 6.5%
Key s upportive secondary safety endpoints
Number of treatment -emergent severe or blood glucose confirmed s ymptomatic hy poglycaemic
epi[INVESTIGATOR_513374] g 26 and 104 weeks of treatment
Trial design
This is a 2- year, multinational, open -label, two -arm parallel, randomised trial with gl ycaemic target 
in subjects with T2DM inadequatel y controlled with OAD(s).
Inadequately  controlled T2DM will be defined as anHbA 1clevel of 7.0- 11.0% (53 -97 mmol/mol), 
both inclusive. A total of 1000 subjects will be randomised in a 1:1 manner using a centralised 
allocation via interactive web response sy stem . 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 9of 95
Subjects will be randomised to receive either once daily  (QD) IDegLira or IGlar in combination 
with OAD(s) at randomisation. Dipeptidy l peptidase -4(DPP -4)inhibitor s and glinides must be 
discontinued at randomisation.
Trial population
Planned number of subjects to be randomised is 1000 (500 per arm).
Key inclusion criteria
Male or female, age ≥18 y ears at the time of signing informed consent
Subjects diagnosed with type 2 diabetes mellitus
HbA 1c7.0−11 .0% (both inclusive) (53 –97 mmol/mol) by [CONTACT_513441]
Body mass index ≥20 kg/m2
Insulin naïve subjects; however short term insulin treatment for a maximum of 14 day s prior to 
the day  of screening is allowed, as is prior insulin trea tment for gestational diabetes
Stable daily dose(s) including any  of the following antidiabetic drug(s)/regimens within 90 day s 
prior to the day  of screeni ng: 
oBiguanides (metformin ≥[ADDRESS_664742])
oOther OAD(s) allowed: sulphony lurea, glinides, pi[INVESTIGATOR_051], and DPP4- inhibitors ( ≥ half of 
the maximum approved dose according to local label or 
maximum tolerated dose as 
documented in subjects medical record)
Key exclusion criteria
Screening calcitonin ≥50 ng/L
Renal impairment estimated Glomerular Filtration Rate (eGFR) <60 ml/min/1.73 m2as per 
CKD -EPI [INVESTIGATOR_513375] -EPI [INVESTIGATOR_513376]
Impaired liver function, defined as ALAT or ASAT ≥2.5 times upper limit of normal
Family  or personal history  of Multiple Endocrine Neoplasia Ty pe 2 or Medullary  Thyroid 
Carcinoma
History  of pancreatitis (acute or chronic)
Treatment with an y medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 d ays before the day  of screening
Anticipated initiation or change in co ncomitant medications for more than [ADDRESS_664743] weight or glucose metabolism (e.g. orlistat, thy roid 
hormones, corticosteroids)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 10of 95
Assessments:
Key efficacy  assessments:
HbA 1c
Body weight
FPG
SMPG
Key safety  assessments:
Hypoglycaemic epi[INVESTIGATOR_1841]
Adverse events
Trial products :
The investigational medicinal products used in this trial are:
IDegLira 100 units/mL  insulin degludec + 3.6 mg/mL liraglutide ,provided in a 3 mL  pre- filled 
PDS290 pen injector for subcutaneous i njection
IGlar 100 units/mL  solution provided in a 3 mL pre -filled Solostar®pen for subcutaneous 
injection
CONFIDENTIAL
Protocol UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664744] no.: 2014 -005639 -15 Version: 1.0 Page: 11of 95
2Flow  chart
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664745]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_664746] RELATED
INFO/ASSESSMENTS
Informed consent X
In/exclusion criteria X X
Randomisation X
Pre-discontinuation of trial product X X X X X X X X X X X
Rescue criteria X X X X X
Withdraw al of consent X X X X X X X X X X X X X3X
Demography4X
Concomitant illness X
Medical history X
Diagnosis of diabetes X
Diabetes treatment history X
Diabetes complications X
Family history of diabetes X
Concomitant medication X X X X X X X X X X X X X X5X5X6X6
Tobacco use (smoking status) X
1Subjects discontinuing trial product prematurely will be asked to attend the end of treatment visit and the 2follow up visits after discontinuation corresponding to V13, V14 and P15. After the 
follow up period the subject should have phone contacts scheduled every 3rdmonth (PX) until the additional premature discontinuation follow up (V13A) visit performed at w eek [ADDRESS_664747] will be collected
6Only concomitant medi cation with the indication diabetes will be collected 
CONFIDENTIAL
Protocol UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664748] no.: 2014 -005639 -15 Version: 1.0 Page: 12of 95
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664749]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
EFFICACY
Glucose metabolism
Fasting plasma glucose X X X X X X X
HbA 1c X X X X X X X X X X X
Fasting C -peptide X X X
Fasting human insulin X X X
Lipi[INVESTIGATOR_805] X X X X
Body m easurements
Height X
Body weight7X X X X X X X X
BMI X
Self m easured plasma glucose
QD8X X X X X X X X X X X X
9-point profile9X X X
SAFETY
Adverse events X X X X X X X X X X X X X X X10X11X11
Hypoglycaemic epi[INVESTIGATOR_1841] X X X X X X X X X X X X X
Techn ical complaints X X X X X X X X X X X X
ECG X X12
7Body weight should be measured fasting except for V1
8Subjects should measure QD Self measured plasma glucose (SMPG) fasting prior to breakfast.  Diabetes medication should be wit hheld until after the SMPG measurement
99-point profile should be measured within 1 week prior to the site visit (on a day where unusual strenuous exercise is not anti cipated)
10Only AE information for potential major adverse cardiovascular events (MACE) will be collected
11Only AE information for potential major adverse cardiovascular events (MACE) and SAE information will be collected
12ECG obtained within 2 weeks prior to V13 is acceptable if results are available for evaluation at V13
CONFIDENTIAL
Protocol UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664750] no.: 2014 -005639 -15 Version: 1.0 Page: 13of 95
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664751]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Eye examination X13X14
Physical examination X X
Vital signs X X X X X X X
Biochemistry15X X X X X
Haemat ology16X X X X X
Hormo nes(calcitonin) X X X X X X X X X X
Urinalysis (albumin:creatinine ratio) X X X X X X
Pregn ancy test17X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) X
OTHER ASSESSMENTS
Barri ers in Diabetes Treatment X
PRO questionnaires
TRIM -D X X X
SF36v2 X X X
TRIAL MATERIAL
Dispensing trial product   X X X X X X X X X X
IWRS call X X X X X X X X X X X X
Drug accountability X X X X X X X X X X X
REMINDERS
13Eye examination performed within [ADDRESS_664752] the screening assessment if results are available for evaluation at V2 
14Eye examination performed within 2 weeks prior to V13 is acceptable if results are available for evaluation at V13
15Amylase, lipase, ALAT, albumin, alkaline phosphatase, ASAT, bilirubins total, calcium ionized ,creatinine, potassium and sodium
16Erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes, differential count (eosinophils, neutrophils, basophils, ly mphoc ytes and monocytes)
17For women of childbearing potential a bl ood sample pregnancy test ( serum hCG ) must be performed at V1 and V13. Additionally, a urine pregnancy test must be performed at site if 
pregnancy is suspected or if a menstrual period is missed . If the subject reports missing menstrual period at a phone contact, the subject will have to attend the site for an unsched uled visit 
as soon as possible to have a urine pregnancy test performed. If positive ,a confirmatory serum hCG must be sent to the central laboratory. If required by [CONTACT_1769], pregnancy test may be 
performed regularly
CONFIDENTIAL
Protocol UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664753] no.: 2014 -005639 -15 Version: 1.0 Page: 14of 95
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-d isc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664754]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_664755] in BG meter use X X X
Attend visit fasting X X X X X X X
Make appointment for eye 
examinationX
End of treatment X
Sign off Casebook X18X
End of trial (subject completion) X18X
18Not applicable for subjects that have prematurely discontinued trial product
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 15of 95
3Backgr ound information and rationale for  the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation .Guideline for Good Clinical Practice (ICH GCP)1and applicable regulatory  
requirements, and in accordance with the Declaration of Helsinki.[ADDRESS_664756] of 
the clinical trial at a trial site.
3.1 Background information
Insulin degludec/liraglutide ( IDegLira)is a combination product of insulin degludec (IDeg) and 
liraglutide . It is to be initiated and titrated to achieve adequate gl ycaemic control in a similar way as 
basal insulin therap y. The basal insulin and glucagon -like peptide -1 (GLP-1) analogue combination 
provides complimentary  effects of the two compounds on fasting and postprandial gly caemic 
control in
asingle injection. IDegLira is available on the market as Xultophyand has been 
approved for use in EU and Switzerland. IDegLiraisindicated for the treatment of adults with ty pe 
2 diabetes mellitus (T2DM) to improve gl ycaemic control in combination with oral glucose -
lowering medicinal products when these alone or combined with basal insulin do not provide 
adequate gl ycaemic control. Efficacy  and safet y of IDegLira has been demonstrated in previous 
randomised clinical trials (NN9068 - 3697, -3912, - 3851, - 3951 and -3952) and is currentl y (2nd
quarter 2015) being evaluated in the randomised clinical trials NN9068 -4119 (DUAL 
intensifica tion) and NN9068-4056 (once weekl y titration) . In all finalised clinical trials, I DegLira 
has shown improve dglycaemic control , less weight gain and a lower rate of hypoglycaemic 
epi[INVESTIGATOR_513377]. N o unexpected safety  issues were identified. For more information, 
see the IDegLira Investigator’s Brochure ( IB)current version3and an y updates hereof. 
IDegis a long -acting basal insulin and is available on the market as Tresiba® which is approved for 
use in amongst others EU and Japan. For more details on ID eg see current IB4,any updates hereof 
and locall y approved labelling in countries where itis available.
Liraglutide is a native (human) GL P-[ADDRESS_664757] and available on the market as Victoza®, 
which is approved for use amongst others in Australia, Canada, China, EU, Japan and US for the 
treatment of adults with T2DM to achieve gl ycaemic control. For more details on liraglutide, please 
see the local approved labelling for Victoza®. 
The basal insulin and GLP- 1 analogue combination brings complementary  effects of the two 
compounds on fasting (IDeg and liraglutide) and postprandial (liraglutide) gl ycaemic control. The 
addition of liraglutide to IDegreduces the req uirement of exogenous insulin (i.e. insulin sparing 
effect) hence minimising the risk of hy pogly caemia and weight gain often associated with insulin 
treatment. The inherent weight reducing effect of liraglutide further contributes to the favourable 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 16of [ADDRESS_664758] of liraglutide, liraglutide reduces postprandial glucose excursions while 
reducing the risk of unwanted lowering of inter -prandial or fasti ng glucose.
Insulin Glargine ( IGlar )is a long -acting insulin analogue, on the market as Lantus®, indicated for 
treatment of diabetes mellitus in combination with 
oral antidiabetic drugs (OAD) and as part of a 
basal -bolus insulin regimen. For further details, please refer to the Summary  of Product 
Characteristics5for IGla
r and the local approved label information .
For an assessment of benefits and risks of the trial, see section 18.1.
3.2 Rationale for the trial
Given the progressive nature of T2DM and despi[INVESTIGATOR_513378] , lack of attainment of appropriate gl ycaemic targets is widespread. Current 
antidiabetic therapi[INVESTIGATOR_014], including treatment with basal insulin, may  not provide adequate or sustained 
glycaemic control. In addition, these therapi[INVESTIGATOR_513379].
According to consensus guidance from the American Diabetes Association (ADA) and the 
European Association for the Study  of Diabetes (EASD )6treatment intensificatio n should be 
considered for subjects with T2DM who do not reach the ADA/EASD HbA 1ctarget of 7% within 
3–6 months of treatment7, or the American Association of Clinical Endocrinologists target of HbA 1c
≤ 6.5% .8
This trial generates clinical evidence on durability , efficacy  and safet y of IDegLira in subjects 
inadequatel y controlled on OAD therap y. IDegL ira has previousl y shown benefits compared to 
intensification with basal insulin and liraglutide in terms of glycaemic control (Hb A1c), percentage 
of subjects reaching target of HbA 1c<7% and weight in 26 and 52 weeks trials . Compared to basal 
insulin I DegLira has shown less h ypogl ycaemia. Furthermore, due to slower titration rate of 
liraglutide component in IDegLira compared to treatment with liraglutide alone, a lower rate of 
gastrointestinal side effects wer e also observed
.9,10
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 17of 95
4Objectives and endpoint s
4.1 Objective s
Primary objective
To compare long -term glycaemic control of IDegLira versus IGlar in insulin naïve subjects with
T2DM inadequatel y controlled with OAD(s).
Secondary objective
To compare long -term efficacy  and safety  of IDegLira in insulin naïve subjects with T2DM 
inadequa tely controlled with OAD(s).
4.2 Endpoints
4.2.1 Primary endpoint
The following endpoint will be assessed up to 104 weeks. Time from randomisation to inadequate 
glycaemic control and need for treatment intensification, defined as HbA 1c>7.0% at 2 consecutive 
visits from week 26 (including week 26, ifHbA 1cwas>7% at week 12) .
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
Time from randomisation to HbA 1c>6.5% at 2 consecutive visits from week 26 * (including 
week 26 ,ifHbA 1cwas > 6.5% at week 12)
Change from baseline in HbA 1c after 26 weeks of treatment *
Change from baseline in body  weight afte r 26*and 104 weeks of treatment
Insulin dose after 26 *and 104 weeks of t reatment
Responder after 26 and 104 weeks of treatment (yes/no):
oHbA 1c<7.0%*
oHbA 1c <7.0% without weight gain
oHbA 1c<7.0% without treatment- emergent severe or blood glucose ( BG) confirmed 
symptomatic hy pogly caemic epi[INVESTIGATOR_339663] 12 weeks of treatment
oHbA 1c<7.0% without treatment- emergent severe or BG confirmed s ymptomatic 
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment and without weight gain
oHbA 1c≤6.5%*
oHbA 1c≤6.5% without weight gain
oHbA 1c≤6.5% without treatment -emergent severe or BG confirmed s ymptomatic 
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment
oHbA 1c≤6.5% without treatment -emergent severe or BG c onfirmed s ymptomatic 
hypoglycaemic epi[INVESTIGATOR_339663] 12 weeks of treatment and without weight gain
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 18of 95
Chang e from baseline after 26 weeks of treatment in:
oFasting plasma glucose (FPG)*
o9-point Self - measured plasma glucose (SMPG) profile:
9-point profil e (individual points in the profile) *
Mean of the 9 -point profile
Prandial plasma glucose increments (from before meal to [ADDRESS_664759], lunch and dinner). The mean increment over all meals will be 
derived as the mean of all available meal increments
Chang e from baseline after 104 weeks of treatment in:
oFPG
o9-point SMPG profile:
9-point profile (individual points in the profile)
Mean of the 9 -point profile
Prandial plasma glucose increments (from before meal to [ADDRESS_664760], lunch and dinner). The mean increment over all meals will be 
derived as the mean of all available meal increments
Chang e from baseline after 26 and 
104weeks of treatment in:
oBlood pressure (s ystolic and diastolic)
oFasting C -peptide and fasting human insulin
oFasting lipid profile (cholesterol, low -densit y lipoprotein cholesterol [LDL cholesterol], 
high-densit y lipoprotein cholesterol [HDL cholesterol], very- low-density  lipoprotein 
cholesterol [VLDL cholesterol], triglycerides, and free fat ty acids)
Suppor tive sec ondary safety endpoints
Number of treatment -emergent severe or BG confirmed sy mptomatic hy poglycaemic epi[INVESTIGATOR_513380] 26 and 104 weeks of treatment*
Number of treatment emergent h ypogl ycaemic epi[INVESTIGATOR_513381] 26 
and 104 weeks of treatment
Number of treatment -emergent nocturnal severe or BG confirmed s ymptomatic hy poglycaemic 
epi[INVESTIGATOR_51953] 26 and 104 weeks of treatment
Number of treatment -emergent adverse events (TEAEs) during 26 and 104 weeks of treatment
Change from baseline in clinical evaluation after 104 weeks of treatment:
oEye examination – fundus photograph y/dilated fundoscopy
oElectrocardiogram (ECG)
oUrine albumin/creatinine ratio
Change from baseline after 26 and 104 weeks of treatment:
oPulse 
Change from baseline in laboratory  assessments after 26 and 104 weeks of treatment:
oBiochemistry
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 19of 95
oHaematology
oCalcitonin
Supportive secondary health economics endpoints
Change from baseline in pati ent reported outcomes (PRO) after 26 and 104 weeks of treatment:
oMedical outcomes study  36-item short form version 2 (SF -36v2)
oTreatment related impact measure (TRIM -D)
* Key  supportive secondary  endpoint prospectively  selected for disclosure (e.g. clinicaltrials.gov 
and EudraCT)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 20of 95
5Trial design
5.1 Type of trial
This is a 2- year (104- week), m ultinational, open- label, two -arm parallel, randomised trial with 
glycaemic target in subjects with T2DM inadequately
 controlled with OAD(s).
Inadequately  controlled T2DM will be defined as an HbA 1clevel of 7.0- 11.0% (53 -97 mmol/mol), 
both inclusive. A t otal of 1000 subjects will be randomised in a 1:1 manner using a centralised 
allocation via an interactive web response s ystem ( IWRS ). 
Subjects will be randomise d to receive either IDegLira or IGlar once dail y (QD) in combination 
with OAD(s) at randomisat ion. Dipeptidy l peptidase -4 (DPP-4)inhibitor s and glinides must be 
discontinued at randomisation.
The total trial duration will be approximately  110 weeks, consisting of a 2- week screening period, a 
104-week treatment period, and 2follow -up contacts (FU1 and FU2). FU1 is scheduled 7 day s (+ 3 
days) after last dose of trial product, and FU2 is scheduled 30 day s (+ 3 days) after last dose of trial 
product. 
The purpose of FU1 is to collect all TE AEs and the purpose of FU2 is to collect potential 
major advers e cardiovascular events (MACE) occurring in the period betw een the 2follow -up 
contacts.
Figure 5–1 Trial design 
5.2 Rationale for trial design
The overall rationale for the trial design is to demonstrate the long -term gly caemic control on 
IDegLira compared to IGlar in a 104
-week treatment period. By [CONTACT_513442] a 
longer treatment duration of IDegLira in a setting more in alignment with clinical practice th an 
previous rand omised IDegLira trials will be investigated .
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 21of 95
The open- label trial design and the visit schedule are chosen to align with clinical practice in order 
to ensure insulin titration based on SMPG values and to ensure the improvement in gl ycaemic 
control which could be expected in the clinic. T he titration is in accordance with apredefined 
treatment algorithm. Please see Table 8–1. 
5.3 Treatment of subjects
Subjects with T2DM with OAD(s) in accordance with the inclusion and exclusion criteria are 
eligible for the trial. When randomised, the subjects will receive one of the treatments described 
below:
IDegLira added to OAD (s)treatment. IDegLira will be given s.c.QD. The recommended 
starting dose of IDegL ira is 10 dose steps (1 0 units I Deg/0.36 mg liraglutide), and will be 
titrated according to a predefined titration algor ithm twice weekly (see section 8.1)to a 
maximum dose of 50 dose steps (50 units IDeg /1.8 mg liraglutide) aiming to reach FPG target 
between 4.0–5.0 mmol/L (72 –90 mg/dL) 
IGlar added to OAD (s)treatment. IGlar will be given s.c. QD at a starting dose of 
10 units and 
will be titrated according to a predefined titration algorithm twice weekl y (see section 8.1) , with 
no prede fined maximum dose, aiming to reach FPG target between 4.0 −5.0 mmol/L  (72−90 
mg/dL)
All subjects will continue with the pre- trial OAD(s) except DPP -[ADDRESS_664761] (IDegLira or IGlar ) is added to sulphony lurea 
therap y, a reduction in the dose of sulp hony lurea should be considered based on gl ycaemic 
response .
The dose and freque ncy of OAD(s) should not be changed during the trial except for safet y reasons . 
The unchanged OAD doses should be confirmed at each visit and recorded in the subject’s medical 
record and in the electronic case report form (eCRF) to verify  compliance. Dose change in OAD(s) 
for a maximum duration of 14 day s is allowed for safet y reasons based on the Inve stigator's 
judgement. If a change in OAD dose has occurred, the duration and reason for the change should be 
recorded in subject’s me dical records and in the eCRF. 
The trial products are described in section 9.
Thetreatment du ration with trial products fo r individual subjects is planned for [ADDRESS_664762] 
at the discretion of the investigator. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 22of [ADDRESS_664763] injectable (or as add on to ongoing GLP -
1 treatment) . Basal insulin will not be effective in all patients and some will need higher doses 
which could results in risk of hypoglycaemia and weight gain .In addition, these therapi[INVESTIGATOR_513382]. I n this trial the overall rationale is to demonstrate 
long-term efficacy  ofIDegLira compared to IGlar. IGlar has been chosen as it is currently  the most 
widely  used basal insulin in many  countries.
The start dose of IDegLira corresponds to the starting dose of insulin tr eatment in type 2 diabetes 
population in clinical practice and as recommended in the IDegLira label .
Both IDegL ira and I Glar will be titrated twice weekly following the same titration algorithm (see 
section 8.1).
All subjects , in both arms ,will continue on metformin and pi[INVESTIGATOR_513383] -trial dose. DPP-[ADDRESS_664764] is added in order 
to decrease the risk of h ypogl ycaemia .
The treatment period of 104 week was chosen to demonstrate long -term efficacy and safetyof the 
trial products.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 23of 95
6Trial population
6.1 Num ber of subjects 
Number of subjects planned to be screened: 1200
Number of subjects planned to be randomised: 1000
Mexico :90 subjects are planned to be random ised/started on trial product in Mexico
Number of subjects expected to complete the trial (on trial product) : [ADDRESS_664765] be answered “ yes”.
1.Informed consent obtained before an y trial -related activities. Trial- related act ivities are an y 
procedures that are carried out as part of the trial, including activities to dete rmine suitability  for 
the trial
2.Male or female, age ≥18 years at the t ime of signing informed consent
3.Subjects diagnosed (clinically ) with type 2 diabetes me llitus prior to the day of screening
4.HbA 1c7.0−11 .0% (both inclusive) (53 –97 mmol/mol) by [CONTACT_513441]
5.Body mass index (BMI) ≥20 kg/m2
6.Insulin naïve subjects; however short term insulin treatment for a maximum of 14 day s prior to 
the day  ofscreening is allowed, as is prior insulin trea tment for gestational diabetes
7.Stable daily
 dose(s) including any  of the following antidiabetic drug(s)/regimens within 90 day s 
prior to the day  of screening: 
Biguanides (metformin ≥[ADDRESS_664766])
Other OAD(s) allowed: sulphony lurea, glinides, pi[INVESTIGATOR_051], and DPP4- inhibitors ( ≥half of 
the maximum approved dose according to local label or maximum tolerated dose as 
docume nted in subject medical rec ord)
6.[ADDRESS_664767] be answered "no".
1.Known or suspected h ypersensitivity  to tri al products or related products
2.Previous participation in this trial. Participation is defined as signed informed conse nt. Re-
screening is not allowed
3.Female who is pregnant, breast
-feeding or intend to become pregnant or of child -bearing 
potential not using adequate contraceptive methods (adequate contraceptive measures as 
required b y local regulation or practice)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 24of 95
Brazil: For women who expressly  declare free of the risk of pregnancy , either by  [CONTACT_513443] y with no birth potential risk, use of contraceptiv e 
method will not be mandatory .
[LOCATION_008] : Adequate contraceptive m easures are defined as established use of oral, 
injected or implanted hormonal methods of contraception, placement of an intrauterine device 
or intrauterine s ystem, barrier methods of contraception (condom or occlusive cap with 
spermicidal foam/gel/film/cr eam/suppository ), female sterilisation, male sterilisation (where 
partner is sole partner of subject), or true abstinence (when in line with preferred and usual 
lifesty le).
4.Receipt of an y investigational medicinal product wi thin 90 day s prior to screening
Brazil: Participation in other trials within 1 y ear prior to screening visit (visit 1) unless there is 
a direct benefit to the research subject at the investigator’s discretion.
5.Any disorder which in the opi[INVESTIGATOR_513384]’s safet y or 
compliance with the protocol
6. Screening calcitonin ≥ 50 ng/L
7.Renal impairment estimated Glomerular Filtration Rate (eGFR) <60 ml/min/1.73 m2as per 
CKD -EPI [INVESTIGATOR_513375]- EPI [INVESTIGATOR_513385]11
8.Impaire d liver function, defined as AL AT or AS AT ≥ 2.5 times upper limit of normal
9.Acute decompensation of gl ycaemic control requiring immediate intensification of treatment to 
prevent severe metabolic dy sregulation (e.g. diabetes ketoacidosis) in the previous 90 day s prior 
to the day  of the screening
10.Family  or personal history  of Multiple Endocrine Neoplasia Ty pe 2 or Medullary  Thyroids
Carcinoma
11.History  of pancreatitis (acute or chronic)
12.Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_513386]/or 
transient ischaemic attack within the past 180 days prior to the day  of scree ning
13.Subjects presently  classified as being in NYHA Class IV
14.Planned coronary , carotid or peri pheral artery  revascularisation
15.Inadequately  treated blood pressure as defined as Class 2 hy pertension or higher (s ystolic ≥
160mmHg or diastolic ≥100 mmHg) at screening
16.Treatment with an y medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of [ADDRESS_664768] weight or glucose metabolism (e.g. orlistat, thy roid 
hormones, corticosteroids)
18.Proliferative retinopathy  or maculopathy  requiring acute treatment as verified by  [CONTACT_513444] [ADDRESS_664769] 5 y ears (except basal and squamous 
cell skin cancer and in -situ carcinomas)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 25of [ADDRESS_664770] meets rescue criteria orif following applies:
Investigator su spect acute pancreatitis. All drugs suspected to relate to this condition must be 
discontinued until confirmatory  tests have been conducted and appropriate treatment should be 
initiated
The trial product must be permanentl y discontinued if the following applies:
Included in the trial in violation of the inclusion and/or exclusion criteria
HbA 1cis >7% measured at 2 consecutive visits from week 26 (including week 26 if HbA 1cwas 
>7% at week 12)
Pregnancy
Intention of becoming pregnant
Participation in an other clini cal trial throughout the trial
In case the c alcitonin value is >50 ng/L . Please see Appendix B
Initiation or significant change in concomitant medications (in excess of 14 days) which in the 
investigator’s opi[INVESTIGATOR_513387]
Subjects that are diagnosed with acute pancreatitis (as a minimum 2 of 3: characteristic 
abdominal pain, am ylase and/or lipase > 3x upper normal range or characteristic findings on 
ultrasound, computerised axial tomograph y/magnetic resonance imaging)
Permanent premature discontinuation of treatment with trial product will notlead to subject 
withdrawal from the trial. Trial product may  be permanently  discontinued at the investigator’s 
discreti on in case of a safety  concern, unacceptable intolerability , or if a subject is judged to be non-
compliant with trial procedures.
6.4.1 Rescue criteria
If the fasting SMPG values taken on 3 consecutive day s or if any  of the FPG samples anal ysed by 
[CONTACT_513445]:
15.0 mmol/L  (270 mg/dL) from baseline to week 6,
13.3 mmol/L  (240 mg/dL) from week 7 to week 12,
11.1 mmol/L  (200 mg/dL) from week [ADDRESS_664771].
See procedures for premature discontinuation further described in section 8.1.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 26of [ADDRESS_664772] who a grees to provide information concerning morbidities which are relevant for the 
assessments of cardiovascular outcomes or other serious adverse events ( SAE )at the planned end of 
the trial isnot to be considered withdrawn from the trial. These subjects should be followed as 
“premature discontinued of trial product ”, see section 6.4. 
Only subjects who decline an y further contact [CONTACT_513446], and hence do not 
agree to report information which is relevant for the assessments of cardiovascular outcomes or
other SAEs at the EOT should be considered as withdrawn from the trial.
Subjects who consider withdrawing informed consent should as a minimum be encouraged to have 
procedures perf ormed according to EOT visit 13and the 2 follow up contacts (see section 2).
Please see section 8.1for procedure to be performed in case of subject withdrawal.
6.[ADDRESS_664773] inadequate glycaemic control with metformin ± other OAD(s) in 
need of treatment intensification to achieve gly caemic control are the target population for inclusion 
in the trial.
Eligible subjects will have an HbA 1clevel of 7.0- 11.0% (53 -97 mmol/mol), both inclusive in order 
to include a T2DM population with OAD(s) who are not optimally  controlled on their current 
treatment . These subjects may benefit from a treatment regimen with anticipated less risk of 
hypoglycaemia and weight gain, when IDegL ira treatment is added . 
Stable diabetes treatment for [ADDRESS_664774] weeks of the trial
.
The BMI limit of ≥ 20 kg/m2is chosen to include as broad a population as possible representative of 
a T2DM populati on.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 27of 95
7Milesto nes
Planned duration of recruitment period  (i.e. first subject first visit ( FSFV) – last subject f irst visit 
(LSFV)): [ADDRESS_664775] visit . 
Recruitment:
Recruitment will 
be closed as soon as the total number of planned subject s to be randomised is 
achieved, taking the number of screened subjects and the screening failure rate into account. 
The screening and randomi
sation rate will b e followed closel y via I WRS in order to estimate when 
to stop screening . All investigators will be notified immediately  when the recruitment period ends, 
after which no further subj ects may  be screened and the I WRS will be closed for further screening. 
All subjects included in the screening period and eligible for randomisati on can be randomised.
Trial r egistration:
In
formation of the trial will be disclosed at clinicaltrials.gov and novonordisk -trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure12, it will also be 
disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (I CMJE)13, the Food and Drug Administration Amendment Act (FDAAA)14, 
European Commission Requirements15,
 [ADDRESS_664776] at these web sites, 
Novo Nordisk may
 disclose the investigator’s contact [CONTACT_18026]. As a result of increas ing 
requirements for transparency , some countries require public disclosure of investigator names and 
their affiliatio
ns.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 28of [ADDRESS_664777] the results.
Timing of the site visits, phone contacts, visit windows and the assessments to be performed are 
specified in the flow chart (see section 2).
8.[ADDRESS_664778] be documented with the investigator´s dated signature [CONTACT_513475]/or in the subject´s medical record . The signed documents must be 
retained at the trial site as source documentation.
Visit schedule
It is the responsibility  of the investigator to ensure that all site visits and phone contacts occur 
according to the flow chart ( section 2). A phone contact [CONTACT_513447] a site visit, if needed. 
All visit dates are calculated in relation to visit 2 (randomisation) excep t for visit 14 (FU1) which 
should take place 7 day s (+ 3 day s) after last dose of trial product. Likewise visit 15 (FU2) should 
take place 30 day s (+ 3 day s) after last dose of trial product.
8.1.[ADDRESS_664779] and other glucose lowering agents should be withheld on the 
day of the visit until blood sampling, fasting SMP G and bod y weight (if applicable) ha vebeen 
performed. Any other prescribed medication should be taken as usual. If the subject attends a 
fasting visit in a non -fasting state the blood sampling and bod y weight procedures should be re -
scheduled within the visit window. 
8.1.2 Screening (visit 1) 
Informed consent pr ocess
Before screening, the investigator must provide the subject with verbal and written information 
about the trial. Informed consent must be obtained before any  trial related activity , see section 18.2. 
The date of informed consent must be transcribed into the eCRF for all screened subjects. 
Screening
Screening of subjects will be registered using IWRS (see section 10). Each subject will be assigned 
a unique 6- digit subject number which will remain the same throughout the trial. The first three 
digits in the subject ID number will con sist of the site number and the last three digits of the subject 
ID number will indicate the individual subject number.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 29of [ADDRESS_664780] address(es) and phone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. The subject screening log and subject enrolment log may  be combined in one list. 
Screening failures
If a screened subject for any  reason is not eligible the subject will be conside red a screening failure. 
A screening failure session must be made in the IWRS. The case book must be signed. 
For screening failures the screening failure for m in the eCRF must be completed with the reason for 
not continuing in the trial. Serious and non-s erious adverse events ( AEs)from screening failures 
must be transcribed b y the investigator into the eCRF. Follow -up of SAEs must be carried out 
according to section 12. Screening failures experiencing an AE that would othe rwise qualify  for 
adjudication will not be adjudicated as no trial product has been administered (See section 12) . 
Re-sampling or re -screening is notallow ed if the subject has failed one of the inclusion or exclusion 
criteria . Exception to this is if the initial blood samples are los t or haemolysed and analy sis is not 
possible at the central laboratory . 
8.1.3 Randomisation (visit 2) 
Randomisation must not take place more than [ADDRESS_664781] be available 
and reviewed b y the investigator and the inclusion/exclusion criteria must be carefull y reviewed to 
ensure the subject is eligible prior to th e randomisation. 
Randomisation of subjects will be done using the I WRS (see section 10). 
At visit [ADDRESS_664782] be discontinued at the day  of randomisation.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 30of [ADDRESS_664783] the subjects in initiating the new treatment .
Treatm ent regimen
All subjects w ill start on 10 
dose steps (10 units of IDeg and 0.36 mg of liraglutide) or 10 units of 
IGlar QD. Maximum dose for IDegLira is 50 dose steps (50 units of IDeg and 1.8 mg of 
liraglutide). Th ere is no predefined maximum dose of IGlar .
Injection area
IDegLira or IGlar should be injected s .c. into the thigh, upper arm (deltoid area) or the abdomen. It 
is recommended that the chosen region is the same throughout the trial. Rotation of injection sites 
within a given region is preferable .
Time of injection
IDegLira or IGlar should be injected QD at an y time of the day , but preferably  at the same time of 
day throughout the trial. 
Titration 
Dose will be adjusted twice weekl y by [CONTACT_423] [ADDRESS_664784] SMPG values , measured on the 
day of the titration and the 2 previous day s.Titration should preferabl y be performed on the s ame 
days of the week throughout the trial (E.g., Monday sand Thursday s). The dose adjustment will be 
performed according to Table 8–1.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 31of 95
Table 8–[ADDRESS_664785] plasma glucose 
mmol/L (mg/dL)Twice weekly adjustments :
IDegLira (dose steps)
IGlar (units)
<4.0 (< 72) -2 
4.0-5.0 (72 -90) Noadjustment
>5.0 (> 90) +[ADDRESS_664786] the following data in the diary : 
Subject ID number
Dateand time of next visit or phone contact
Prescribed dose of trial product
Data from SMPG measurements from previous diary , if required to complete next dose 
adjustment
Review signature
[CONTACT_513476]: 
Date, time and valu e of the daily  fasting SMPG measurement s
Date, time and dose of trial product each day
Date, time and value of the 9 -point SMPG profile prior to visit s2, 7 and 13
Hypoglycaemic epi[INVESTIGATOR_1841] (see section 8.4.1)
Any medical issues
Any new/change in medication
Work absence due to a medical issue
The diary  must be reviewed by  [CONTACT_513448]´s, including medical issues and 
concomitant medication, are reported (see sec tion 8.2.1 and 12).
The purpos e of having the subject record date, time and value of the fasting SMPG measurements 
and date, time and dose of trial product dail y is to secure optimal titration. All these daily data must 
be reviewed b y the investigator who must consider whether the reported values f rom the SMPG 
measurements must be reported as hy poglycaemic epi[INVESTIGATOR_1841] (see section 8.4.1 ). Only date, time and 
value of the fasting SMPG measu rements and date, time and dose of trial product for the last 3 day s 
prior to the visit /phone contact [CONTACT_513449]. All other data entered by  [CONTACT_513450].
The investigator should trans cribe the diary  data to the eCRF as soon as possible, preferabl ywithin 
[ADDRESS_664787] be handled
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 32of 95
according to the timelines described in Figure 12–[ADDRESS_664788] be documented either on the document and/or in the subject’s medical 
record. If clarification of entries or discrepancies in the diary is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
Laboratory assessments
The labor atory  anal yses will be handled by a central laboratory . Descriptions of assay  methods, 
laboratory  supplies and procedures for obtaining samples, handling, transportation and storage of 
biological samples and information regarding who will perform the assessments, will be described 
in atrial specific laboratory  manual, provided by  [CONTACT_2237]  (for central laboratory  
details, see Attachment I). 
Laboratory  samples not drawn on the day  of the actual visit should preferably  be drawn on another 
day within the visit window (flow c hart section 2). For some of the samples drawn during the trial 
the subject must be fasting, see the flow chart section [ADDRESS_664789] operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. 
Brazil : All labor atory  results from Brazilian subjects must be provided to the investigator.
Laboratory results will be provided by [CONTACT_513451]. 
For laboratory  results outside the normal range the investigator must specify an evaluation on the 
laboratory  report. The evaluation must follow the categories :
Normal
Abnormal
Was the result clinically  significant ? (Yes/No)
The investigator must review all laboratory  results for concomitant illnesses and AEs and report 
these according to this protocol (see section 8.2.1 and section 12). The review of laboratory  reports 
must be documen ted either on the documents and/or in the subject’s medical record. The laboratory  
report must be evaluated as soon as possible and signed and dated b y the investigator on the day  of 
evaluation. The signed report must be retained at the site as source documentation.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 33of [ADDRESS_664790] are shipped to the 
laboratory  immediatel y after the samples from visit 1 and visit 13 (or visit 13A for premature ly 
discontinued subjects) have been collected.
All samples will be destroy ed on an ongoing basis after the anal ysis or at the latest at the
completion of the clinical trial report (CTR). 
8.1.6 Follow up visits (visit 14 and 15)
FU1 should be scheduled 7 day s (+ 3 day s) after last dose of trial product and FU2 should be 
scheduled 30 day s (+ 3 day s) after last dose of trial product. At FU1 informati on on antidiabetic 
treatment, an y AEs and hypogl ycaemic epi[INVESTIGATOR_513388] [ADDRESS_664791] be performed if:
An AE occurs that needs further attention
Additional laboratory  samples are needed due to an AE requir ing special forms in the eCRF (see 
section 12.2)
A confirmatory  pregnancy  test is needed
A blood re -sampling related to a specific visit (if not possible to schedule the re -sampling within 
the visit window). Only if initial blood sample for some reason was not able to be anal ysed
Confirmatory  FPG test for rescue criteria evaluation
For the above an unscheduled visit form must be completed in the eCRF, indica ting the reason for 
the visit. 
An unscheduled visit form should notbe completed if the subject attends the trial site for a blood re-
sampling within the visit window. Instead a requisition form must be completed with the visit 
number the re -sampling refers to and the data must be entered to the eCRF for the corresponding 
visit. Also, additional trial product dispensing or auxiliary suppl y dispensing does not require the 
use of the unscheduled visit form. An a dditional dispensing s ession should be made in the I WRS 
prior to additional trial product dispensing.
8.1.[ADDRESS_664792] (see section 6.4) willbe called in for an EOT visit corresponding to 
visit 13as soon as possible after discontinuation of trial product (i.e., day  of last dose of trial 
product) .Subject will be asked to br ing the current diary and all dispensed trial product . FU1 and 
FU2 should be performed as described in section
 8.1.6.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 34of [ADDRESS_664793] decides to withdra w from the trial, the investigator should aim to undertake procedur es 
similar to those for visit 13 , FU1 and FU2 (see section 8.1.6) as soon as possible after the last dose 
of trial product .
The end -of-trial form must be completed, and final drug accountabilit y must be performed even if 
the subject is not able to come tothe trial site. A treatment discontinuation session must be made in 
the IWRS. The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing from a trial, the 
investigator must make a reasonable effort to ascertain the reason(s), while fully  respecting the 
subject’s rights. Where the reasons are obtained, the primary  reason for not completing the trial 
must be specified on the end -of-trial form in the eCRF.
8.[ADDRESS_664794] related information 
Demography
Demograph y consists of:
Date of birth (according to local regulations)
Sex
Race (according to local regulations)
Ethnicity  (according to local regulations)
8.2.1 Concomitant illness and medical history
A concomitant illness is any  illness that is present at the start of the trial (i.e. at visit 1) or found as 
a result of a screening procedure. Concomitant illness includ es an y pre -plann ed procedures, surgery 
and an y intermittent illness (e.g. allergies) that may not be apparent at the time of screening. T2DM 
should not be re corded as concomitant illness. Any change to a concomitant illness should be 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 35of [ADDRESS_664795]. The information 
collected for concomitant illness and medical history  should include diagnosis, da te of onset and 
date of resolution or continuation, as applicable.
Diagnosis of dia betes is an account in the eCRF of the date of diagnosis of diabetes. 
Diabetes treatment history/diabetes complication is an account in the eCRF where information 
about cur rent diabetes treatment, dose of current diabetes treatment, start date of current diabetes 
treatment is collected. It is also an account in the eCRF of medical events and complications related 
to diabetes i.e. diabetic retinopathy /neuropathy /nephropathy  and macro angiopathy  (including 
peripheral vascular disease). Details of all relevant diabetes complications must be recorded at trial 
entry  (i.e. at screening visit). The information collected for diabetes complications should include 
diagnosis and date of onset. 
Family history of diabetes is an account in the eCRF where information about the family  history  
of diabetes is collected. 
8.2.[ADDRESS_664796]’s eligibility  to continue in the trial, the monitor must be informed. Please see 
section 6.4.
8.2.3 Smoking status (Tobacco use)
Details of smoking status must be recorded at visit 1. Smoking is defined as smoking at least one
cigarette, cigar or pi[INVESTIGATOR_513389] . The collected information should include whether or not the subject 
smokes or has smoked. If the subject smokes or has smoked, record approximately  when the subject 
started smokin g and, if applicable, when the subject stopped smoking.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 36of 95
8.3 Assessments for efficacy
Body measurements
Height 
Height is measured without shoes in centimetres (cm) or inches (inch) and rounded to the nearest 
cm or inch. 
Body weight
Body weight should be measured without shoes and only wearing light clothing in kilogr ams (kg) 
or pounds (lb) with one decimal. The measurements are to be performed in a fasting state, except 
for the measurement atvisit 1. Body  weight should be assessed with the same equipment 
throughout the trial, if possible. 
Body Mass Index (BMI)
BMI will be automatically calculated in the eCRF once height and weight are entered.
8.3.[ADDRESS_664797] the results of the SMPG values i n the diaries.
Quaque die
Subjects should perform QDSMPG measurement sin a fasting state.For definition of fasting state 
see section 8.1. Diabetes medication (including tr ial products) should be withhel d until after the 
measurement. 
9-point profile
Subjects should perform SMPG measurements and record the obtained values for a 9-point profile 
within a week prior to visit 2, [ADDRESS_664798] does not anticipate unusual 
strenuous exercise .
The SMPG values obtained from the measurements should be recorde d in the diary  (including clock 
time and date for the measu rement) at the following time points, alway s starting with the pre-
breakfast measurement: 
Before breakfast (this will be the SMPG of that day)
[ADDRESS_664799]
Before lunch
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 37of 95
90 min after the start of lunch
Before dinner
90 min after the start of dinner
At bedtime
At 4 am
Before breakfast the following day (this will be the SMPG of that day )
8.4 Assessments for safety
Adverse events (AEs)
All AEs must be collected and reported according to the procedures described in section 12. 
Adverse Events requiring special forms in the eCRF 
For some AEs the investigator must fill in special forms in the eCRF. The AEs that require special 
forms in the eCRF are:
Cardiovascular events
Pancreatitis
Neoplasms
Thyroid disease
In case any of these events fulfil the criteria for a SAE, please report accordingl y. See section 12.2.
Cardiovascular events
Cardiovascular events that are suspected as being related to one of the three categories below 
should be reported on the designated form in the eCRF:
1.Acute coronary syn drome
All ty pes of myocardial infarction (MI) or hospi[INVESTIGATOR_36193], for further 
information (see Appendix A). If an event of acute coronary  syndrome is observed during the trial, 
this must be recorded as an AE and on a specific acute coro nary syndrome form in the eCRF. The 
following information must be reported if available: 
Duration of s ymptoms
Changes in ECG
Collection of cardiac biomarkers
Cardiac imaging
Cardiac stress testing
Angiograph y
Use of thrombol ytic drugs
Coronary  revascularisation
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 38of 95
2.Cerebrovascular events, e.g., stroke or transient ischemic attack (TIA)
If a cerebrovascular event is observed during the trial, this must be recorded as an AE and on a 
specific cerebrovascular event form in the eCRF. The following inform ation must be reported if 
available: 
Type of event (e.g., s troke or TIA )
Contributing condition
Neurologic signs and s ymptoms
History  of neurologic disease
Imaging supporting the condition
Treatment given for the condition
3.Heart failure
If an event of heart failure requiring hospi[INVESTIGATOR_11956] (admission to an in -
patient unit or a visit to an 
emergency  department that results in at least a 24 hour stay) is observed during the trial, this must be 
recorded as an SAE and in addition on a specif ic cardiovascular event form in the eCRF. 
The following information must be reported if available: 
Signs and s ymptoms of heart failure
NYHA Class
Supportive imaging
Supportive laboratory  measurements
Initiation or intensification of treatment for this co ndition
Pancreatitis
If a subject is diagnosed with pancreatitis during the trial, this must be recorded as an AE and on a 
specific p
ancreatitis event form in the eCRF. The following information must be reported if 
available:
Signs and s ymptoms of p ancreatitis
Specific laboratory  test supporting a diagnosis of pancreatitis:
oAmy lase
oLipase
oALAT and AS AT
oBilirubin s, total
oAlkaline Phosphatase
Imaging performed and consistency  with pancreatic disease.
Complications to the event
Relevant risk factors for pancreatic disease including:
oHistory  of gall -stones
oHistory  of pancreatitis
oFamily  history  of pancreatitis
oTrauma
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 39of 95
Neoplasm
All events of neoplasm (excluding thy roid neoplasm, but including malignant neoplasm, in situ 
neoplasm and benign neoplasm) must be recorded as an AE and on a specific neoplasm event form 
in the eCRF. The following information must be reported if available: 
Type of neoplasm
Symptoms leading to identification of event
Diagnostic imaging
Pathological examination results
Treatment for t he event
Participation in screening programs
Risk factors associated to the event
Thyroid disease
Subjects scheduled for thyroidectomy  (partial or total) for any  reason during the trial, must be 
instructed to inform the investigator prior to their operation. If an event of thy roid disease, including 
any thyroid neoplasms observed during the trial, thismust be recorded as an AE and on a specific 
thyroid disease event form in the eCRF. The following information must be reported if available: 
History  of th yroid disease
Signs and s ymptoms leading to investigations of thy roid disease
Specific laboratory  tests describing thy roid function including:
oThyroid stimulating hormone (TSH)
oTotal and free triiodothy ronine ( T3)and thyroxine ( T4)and Free Th yroid Index
oCalcitonin
oThyroid Peroxidase antibodies
oThyroglobulin and Th yroglobulin antibody
oTSH receptor antibody
Diagnostic imaging performed and an y prior imaging supporting the disease history
Pathologic examinations
Treatment given for the condition
Risk factors identified
Family  history  of thyroid disease
8.4.1 Hypog lycaemic epi[INVESTIGATOR_513390] a h ypogl ycaemic epi[INVESTIGATOR_36190].
All plasma glucose values:
≤ 3.9 mmol/L  (70 mg/dL) or 
> 3.9 mmol/L  (70 mg/dL) occurr ingin conjunct ion with hy poglycaemic s ymptoms ,
should be re ported in the diary  according to the instructions below throughout the trial from visit 2 
to vis
it 14. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 40of [ADDRESS_664800] is recommended to measure plasma glucose 
every  15 minutes until the SMPG value is > 3.9 mmol/L  (70 mg/dL) or s ymptoms have been 
resolved in accordance to current guidelines .17
A SMPG value ≤3.9 mmol/L  (70 mg/dL) or h ypogl ycaemic s ymptoms must trigger a 
hypoglycaemic epi[INVESTIGATOR_513391] b y the subject. Repeated SMPG measurements and/or 
symptoms will per default be considered as one h ypogl ycaemic e pi[INVESTIGATOR_41106] a succeeding SMPG 
value is >3.9 mmol/L  (70 mg/dL) and/or symptoms have been resolved. One hy poglycaemic 
epi[INVESTIGATOR_36198]/or sy mptoms. However, each hy poglycaemic 
epi[INVESTIGATOR_513392] a period of maximum [ADDRESS_664801] SMPG value and/or sy mptom.
If a new low SMPG value is measured or the subject still has sy mptoms more than [ADDRESS_664802] should include the following information:
Start d
ate and time of h ypogl ycaemic epi[INVESTIGATOR_1865] 
The plasma glucose level before treating the epi[INVESTIGATOR_1865] (if available) and any  follow up 
measurements
The lowest value measure d during the h ypoglycaemic epi[INVESTIGATOR_215511], the remaining val ues will be kept as source data
Whether the epi[INVESTIGATOR_513393] (Yes/No)
A hy poglycaemic epi[INVESTIGATOR_513394]. 
Whether the subject was able to treat him/herself
If the severity  of a hy pogly caemic epi[INVESTIGATOR_513395], only  one hy pogly caemic epi[INVESTIGATOR_513396] h ypogl ycaemia. 
Date, time and dose of last IDegLira/IGlar administration prior to the epi[INVESTIGATOR_1865]
Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865] 
Whether the epi[INVESTIGATOR_513397]
Worsening of an y concomitant illness (pre -existing illness)
Any sign of fever or other acute disease
Whether the subject was asleep when the epi[INVESTIGATOR_513398], whether the s ymptoms of the epi[INVESTIGATOR_513399]: "Was t he subject able to treat him/herself?" must be answered "No" for 
an epi[INVESTIGATOR_513400], glucagon, or 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 41of [ADDRESS_664803] is unconscious.
If the question "Was the subject able to treat him/he rself?" is answered "No", the following
information should be recorded b y the subject:
Who assisted in the treatment of the hypogly caemic epi[INVESTIGATOR_1865] (i.e. medical person or non-medical  
person)
Where the treatment was administered (i n clinic/emergency room/ ho spi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency  room/hospi[INVESTIGATOR_307], whether they were transported in an 
ambulance or not)
Type of treatment provided by [CONTACT_215559] (i.e. oral carbohydrates, glucagon, IV glucose or  
other)
Were sy
mptoms alleviat ed after administration of treatment?
Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet changed, medication 
error (i.e. overdose, mix -up between products), miscalculation of insulin dose, other factors not
 
listed or unkn own)
Did the subject experience seizure?
Was the subject unconscious/comatose?
Did the subject experience any of the followin
g symptoms18 (layman term used in the diary is 
specified in brackets if different from the protocol term)?
oAutonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
oNeuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, od
d 
behaviour, impaired balance or incoordination  (reduced ability to coordinate movement)
oGeneral malaise: headache or malaise (feeling disco
mfort/unease)
oOther symptoms?
The Investigator must review the diary at each contact [CONTACT_513452][INVESTIGATOR_1841]. The subject must be questioned whether an y of the low values were 
severe i.e. whether the subject was able to self- treat or not. If the subject was not able to self -treat it 
has to be reported as a severe h ypogl ycaemic epi[INVESTIGATOR_36210] a h ypogl ycaemic epi[INVESTIGATOR_215510].
Low SMPG values for non -severe h ypogl ycaemic epi[INVESTIGATOR_36212] a hypogl ycaemic epi[INVESTIGATOR_36213] [ADDRESS_664804] was able to self-treat 
due to decreased validity  of such data .19,20
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 42of [ADDRESS_664805] be re -trained in how to report h ypogl ycaemic epi[INVESTIGATOR_444959] h ypogl ycaemic epi[INVESTIGATOR_1841].
If the h ypogl ycaemic epi [INVESTIGATOR_513401] a SAE then an AE form and a safet y 
information form (SIF) must also be filled in, see section 12.
Please be aware that h ypoglycaemic epi[INVESTIGATOR_513402] y trial drug is given 
i.e.,hypoglycaemic epi[INVESTIGATOR_513403] 2. 
Technical compliants
Technical complaints must be collected and reported according to the procedures described in 
section 12.4
ECG (elect rocard iogram) 
A [ADDRESS_664806] follow the categories:
Normal
Abnormal
Was the result clinically  significant ? (Yes/No)
An ECG performed within 2 weeks prior to visit 13 is acceptabl e, if results are available for
evaluation at visit 13.
Eye examination
Eye examination ( fundus photograph y/dilated fundoscopy )must be performed by  [CONTACT_093], a 
local ophthalmologist or an optometrist according to local practise. Results of t he ey e examination 
must be interpreted, signed and dated b y the investigator to verify  that the data has been reviewed
before randomisation and in order to determine the eligibility  of the subject.
The evaluation must follow the categories:
Normal
Abnormal
Was the result clinically  significant ? (Yes/No)
If an ey e exa mination has been performed within [ADDRESS_664807]'s 
medical records that the procedure was not performed in relation to this trial. 
If an ey e examination has been performed within 2 weeks prior to visit 13 the procedure does not 
need to be repeated, if the results are avai lable for evaluation at visit 13. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 43of [ADDRESS_664808] include: 
General appearance
Head, ears, ey es, nose, throat, neck
Thyroid gland
Respi[INVESTIGATOR_36517]
Cardiovascular s ystem
Gastrointestinal system including mouth
Musculoskeletal sy stem
Central and peripheral nervous sy stem
Skin
Lym ph node palpation
Vital Signs
Diastolic blood pressure, sy stolic blood pressure and pulse should be measured while the subject is 
in a sitting position and after [ADDRESS_664809] be in accordance with the relevant 
exclusion criteria (see section 6.3).
8.5 Laboratory assessments
Blood and urine samples will be collected in accordance with the flow chart (section 2) and 
analysed by [CONTACT_513453] :
Blood samples for efficacy
Glucose metabolism: HbA 1c, fasting plasma glucose, beta cell function (fasting C- peptide and 
fasting human insulin ).Note: Low FPG values reported by  [CONTACT_513454][INVESTIGATOR_1841]; however these should be reported as an AE related to the 
procedure (e.g. a FPG result of 2.9 mmol/L  (52 mg/dL ) should be repor ted as ‘low plasma 
glucose of 2.9 mmol/L  (52 mg/dL)’)
Fasting lipid profile :trigly cerides, cholesterol, LDL cholesterol, HDL cholesterol, VLD L 
cholesterol, free fatty  acids
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 44of 95
Blood and urine samples for safety
Haematology : Ery throcy tes, haematocrit, haemogl obin, leucocy tes, thrombocy tes, differential 
count (eosinophils, neutrophils, basophils, monocy tes and l ymphocy tes)
Biochemistry : Am ylase, lipase, AL AT, AS AT, alkaline p
hosphatase, albumin, bilirubin s total , 
creatinine, potassium, sodium and calcium , ionized
Hormones : Calcitonin . In case an ycalcitonin value at an y time in the trial is ≥ 10 ng/L the 
algorithm in 
Appendix Bmust be followed
Pregnancy  test: Females of childbearing potential will have a human chorionic gonadotropin 
(hCG) serum pregnancy  test performed . Urine pregnancy  test using urine -sticks will be 
performed at site during the trial for females of childbearing potential if a menstrual period is 
missed or pregnancy  is suspected. If a urine test is positive, a confirmatory  serum -hCG test m ust 
be taken and sent to the central laboratory  for analy sis. It should be documented in the eCRF in 
an unscheduled visit, describing “pregnancy  test” under “other”
A urinaly sis to determine the albumin/creatinine ratio .Urine will be collected at site and sent to 
the 
central laboratory  for anal ysis
8.[ADDRESS_664810] be documented either on the documents and/or in the subject’s 
medical record.
If clarification of entries or discrepancies in the questionnaires is needed, the subject must be 
questioned and a conclusion made in t he subject’s medical record. Care must be taken not to bias 
the subject.
All responses to the questionnaires must be transcribed into the eCRF. 
Novo Nordisk baseline questionnaire
The Novo Nordisk baseline questionnaire: Barriers in Diabetes Treatment must be completed in 
accordance with the flowchart (section 2).
Patient reported outcomes
The following PRO questionnaires must be completed in accorda nce with the flowchart (section
 2):
SF-36v221
TRIM-D22
The PRO ques tionnaires should be completed at the s ame time point of the visit for all visits, e.g. 
before seeing the doctor.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 45of [ADDRESS_664811] of the 
importance of following the instructions given including taking the trial produ cts as prescribed.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 46of 95
9Trial supplies
Trial supplies comprise trial products and auxiliary  supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM).
Trial products must not be dispensed to any person not included in the trial. 
Trial product must not be used, if it does not appear clear and colourless. 
9.1 Trial products
The following trial products are considered as investigational medicinal products andwill be 
provided b y Novo Nordisk A/S, Denmark:
Table 9–1 Investigational medicinal products 
Investigational m edicinal 
products Strength Dosage formRoute of 
administrationContainer/
delivery device 
Insulin Degludec/Liraglutide100 units/mL + 
3.6 mg/mLSolution for
injectionSolution for s.c.
Injection3 mL pre -filled 
PDS290 pen 
injector
Insulin Glargine
100 units/mL3 mL pre -filled 
SoloStar®
Pre-trial OADs are considered as non -investigat ional medicinal products (NIMPs) and will not be 
supplied by [CONTACT_3454] , unless required b y local law. 
Slovakia : Pre-trial OADs and/or rescue medication used during the trial will not be supplied by  
[CONTACT_3454], however these medications will be reimbursed b y Novo Nordisk Slovakia s.r.o.
Argentina
: NIMP s should be purchased or otherwise deli vered to subjects in accordance with local 
health plans.
9.2 Labelling
The trial products will be labelled in accordance with Annex 1323, local regulations and trial 
requirements.
Each trial site will be supplied with sufficient trial products for the trial on an on -going basis 
controlled by  [CONTACT_941] I WRS. Dispensing unit numbers (DUNs) will be distributed to the trial sites 
according to enrolment and randomisation. 
The investigator mus t document that direction for use is given to the subject verbal ly and in writing 
at the first dispensing visit ( visit 2) .On all other dispensing visits the direction for use must be 
given in writing.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 47of 95
9.3 Storage 
Storage and in-use conditions of the trial pr oducts are outlined in Table 9–2.
Table 9–2 Storage conditions for investigational medicinal products
Investigational 
medicinal productsStorage conditions
(not-in-use)In-use conditions In-use time*
Insulin 
Degludec/Liraglutide
Store in refrigerator (2 °C-
8°C/36 °F-46°F)
Do not freeze
Protect from lightStore below  30°C (86°F)
Do not freeze
Protect from lightUse within 3 
weeks
Insulin Glargine Do not store above 25°C
US: Do not store above 30°C 
(86°F)
Do not refrigerate
Protect from lightUse within 4 
weeks
* In-use time starts when the produ ct is taken out of the refrigerator in the subject’s home
The investigator must ensure the availability  of proper storage conditions, and also record and 
evaluate the temperature. The investigator must inform Novo Nordisk immediately if an y trial 
product has been stored outside specified conditions (e.g. outside temperature range).
Trial product that has been stored improperl y must not be dispensed to an y subject before it has 
been evaluated and approved for further use b y Novo Nordisk. The investigator must take 
appropriate action to ensure correct storage.
9.[ADDRESS_664812] (used/partly  used or unused 
including empt y packaging material) can be stored at room temperature and must be stored 
separately  from non -allocated trial product. Drug accountability  is performed by  [CONTACT_10540] I WRS. 
Only  dispensed DUNs returned by  [CONTACT_423] (used/partly  used or unused) are accounted for.
Destruction will be done according to local procedures after accountability  is finalised and verified 
by [CONTACT_2037]. Destruction of products must be documented.
9.5 Auxiliary supplies
The following will be provided by  [CONTACT_215571]:
Directions for Use for pen devices
Needles for pen devices (needles used must not be longer than 8 mm )
BG meters and BG meter auxiliaries
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 48of [ADDRESS_664813] be restricted to and controlled by  [CONTACT_36301]. 
IWRS is used for: 
Screening
Screening failure
Randomisation
Medication arrival
Dispensing
Treatment d iscontinuation
Completion
Drug accountability
Data change
It is important that the trial site dispenses the trial products alloc ated b y IWRS in order to:
Provide the correct trial product (correct DUN) according to randomisation and dis pensing visits
Secure available stock at site to cover the drug supply  need for all enrolled subjects
Ensure that no subjects receive trial product that will expi[INVESTIGATOR_513404]
Secure that drug accountability  is possible.
IWRS user manuals
will be provided to each trial site.
11Random isation pr ocedur eand br eaking of blinded codes
At the randomisation visit (V2) subjects will be randomised either to QD IDegL ira or IGlar in 
combination with OAD(s). Dipeptidy l peptidase -4 (DPP -4) inhibitors and glinides must be 
discontinued at randomisation.
The randomisation will be carried out in a 1:1 manner using IWRS (500 subjects in each treatment 
arm). 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 49of 95
12Adverse events, and technical complaints and pr egnancies
12.1 Definitions
Adverse ev ent 
An adverse event (AE) is any  untoward medical occurrence in a subject administered a product, and 
which does not necessarily  have a causal relationship with this treatment. 
An AE can therefore be any  unfavourable and unintended sign (including an abnormal laboratory  
finding), s ymptom or disease temporally  associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
A clinically  significant wor sening of a concomitant illness
A clinical laboratory  adverse event (CL AE): a clinical laboratory  abnormality  which is clinicall y 
significant, i.e. an abnormality  that suggests a disease and/or organ toxicity  and is of a severity  
that requires active management. Active management includes active treatment or further 
investiga tions, for example change of medicine dose or more frequent f ollow -up due to the 
abnormality
The following should notbe reported as AEs:
Pre-existing conditions, including those found as a result of screening procedures (pre -existing 
conditions should be reported as medical history  or concomitant illness)
Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity  after the subject has signed the informed consent
Non-serious h ypogl ycaem ia is an AE, but is reported on a h ypogl ycaemic epi[INVESTIGATOR_36219], see section 8.4.1
The following three definitions are used wh en assessing an AE:
Severity 
oMild - no or transient symptoms, no interference with the subject's daily  activities
oModerate -marked s ymptoms, moderate interference with the subject's daily  activities
oSevere -considerable interference with the subject's daily activities; unacceptable
Causality 
Relationship between an AE and the relevant trial product(s): 
oProbable -Good reason and sufficient documentation to assume a causal relationship
oPossible -A causal relationship is conc eivable and cannot be dismissed
oUnlikely -The event is most likely  related to aetiolog y other than the trial product
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 50of 95
Final outcome
oRecovered/resolved - The subject has full y recovered, or b y medical or surgical treatment 
the condition has returned to the level observed at the first trial- related activity  after the 
subject signed the inform ed consent
oRecovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only  applicable if the subject has completed the tr ial or has died 
from another AE
oRecovered/resolved with sequelae -The subject has recovered from the condition, but with 
lasting effect due to a disease, injury , treatment or procedure. If a sequela emeets an SAE 
criterion, th e AE must be reported as an SAE
oNot recovered /not resolved - The condition of the subject has not improved and the 
symptoms are unchang ed, or the outcome is not known
oFatal -This term is only  applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs i n a subject before he/she died should be 
assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal out come must be reported as an 
SAE
oUnknown -This term is only applicabl e if the subject is lost to follow -up
Serious adverse event
A SAE is an experience that at an y dose results in any of the following:
Death
A life -threateningaexperience
In-patient hospi[INVESTIGATOR_513405]
A persistent or significant disability  or incapacityc
A congenital anomal y or birth defect
Important medical events that may  not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement -
they may  jeopardise the subject and may  require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd
Suspi[INVESTIGATOR_513406] s be considered an 
SAE
aThe term "life threatening" in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hy pothetically  might 
have caused death if it was more severe.
bThe term "hospi[INVESTIGATOR_11956]" is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]- patient, irrespective of the duration of ph ysical stay , 
or 
–Stays at the hospi[INVESTIGATOR_36223] 24 hours
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 51of [ADDRESS_664814]'s ability to conduct normal life functions (e.g. following the 
event or clini cal investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body  function or structure, ph ysical activity and/or 
quality  of life).
dFor example intensive treatment in an emergency  room or at home of allergic bronchospasm, 
blood dy scrasiasis or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug 
dependency  or drug abuse.
Non-serious adverse event
A non- serious AE is an y AE which does not fulfil the definition of an SAE.
Med ical event of special interest
A medical event of special interest (MESI) is an event which, in the evaluation of safet y, has a 
special focus. A MESI  is an AE (SAE or non- serious AE) which fulfils one or more of the below 
defined criteria.
1.Medication er rors concerning trial products:
Administration of wro ng drug or use of wrong device
Note: Use of wrong DUN is not considered a medication error unless it results in administration 
of wrong drug. 
Wrong route of administration, such as intram uscular instead of subcutaneous
Administration of an overdose with the intention to ca use harm (e.g. suicide attempt)
Accidental administration of a lower or higher dose than intended. That is a dose lower or 
higher than 20% of the intended dose; however the administered dose must deviate from the 
intended dose to an extent where clinical consequences for the trial subject were likel y to 
happen as judged b y the investigator, although they did not necessaril y occur
When reporting a MESI (medication error) , the following fo rms must be completed: the AE form, 
SIF and the specific medication error MESI form as described in section 12.2 and also illustrated in 
Figure 12–1.
Adverse event s with additional data collection
AEs with additional data collection are AEs defined as critical for the evaluation of pro duct safet y. 
For these AEs the i nvestigator must fill in additional forms in the eCRF. The AEs that require 
additional forms in the eCRF are:
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 52of 95
Cardiovascular events:
oAcut e coronary  syndrome
oCereb rovascular event
oHeart failure requiring hospi[INVESTIGATOR_063]
Pancreatitis
Neoplasms
Thyroid disease 
For detailed in formation on AEs with additional data collection, see section 8.4.
Along with fatal events, certain events of interest will be adjudicated b y an external independent 
Event Adjudication Committee (EAC ) as described in section 12.7.2. For further information 
regarding definitions, rationales, and events that will be adjudicated see Appendix A. 
Major Adverse Cardiovascular Event
AMajor Adverse Cardiova scular Event (MACE ) is any  AE which can be categorised into the 
following groups:
Cardiovascular Death
Myocardial Infarction
Hospi[INVESTIGATOR_329890] 
Transient Ischemic Attack and Stroke 
Heart Failure Event (requiring hospi[INVESTIGATOR_11956])
Cardiac procedures
oInterventional Cardiology
oPeripheral Vascular Intervention 
oStent Thrombosis
Technical com plaint s
A technical complaint is any  written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
The phy sical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
The packaging material (e.g. leakage, cracks, rubber membrane issues or errors in labelling text)
Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 53of [ADDRESS_664815] prematurel y (see section 6.4) willbe contact[CONTACT_457]  3rdmonth 
and asked for information about antidiabetic medication and serious adverse events (SAEs). The se
subject sshould finally  come in for a visit 13A a t week 104, onl y to assess anti diabetic medication, 
SAEs and a blood sample to measu re HbA 1c.
The events must be recorded in the applicable eCRF forms in a timely  manner, see timelines below 
andFigure 
12–1.
During each contact [CONTACT_345992], the subject must be asked about AEs and technical 
complaints, for example by  [CONTACT_7939]: "Have y ou experienced an y problems since the last contact?"
All AEs, observed by [CONTACT_36305], must be reported by  [CONTACT_1755] e valuated. 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: 
IDegLira: Current version of the Company  Core Data Sheet or any  updates hereof .
IGlar: European Summary  of Product Characteristics curre nt versi on or an y updates hereof
.[ADDRESS_664816] be 
completed.
MESI s (medication errors), regardless of seriousness, must be reported using both the AE form and
the SI Fanda MESI  form. The MESI  form is a form tailored to collect specific information related 
to the individual MESI .
For AEs requiring adjudication, the event specific adjudication form must be completed.
The AE form for a non -serious AE not fulfilling the MESI  oradditional data collection criteria 
should be signed when the event is resolved or at the end of the trial.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 54of [ADDRESS_664817] complete the following forms in the eCRF within the specified timelines:
SAEs: The AE form within 24 hours and the SI Fwithin 5 calendar days of the investigator's 
first knowledge of the SAE. SAEs with additional data collection: also the specific event form 
within 14 calendar days of the investigator's first knowledge of the AE. Allforms must be 
signed within 7 calendar days from the date the information was entered in the eCRF
SAEs fulfilling the MESI criteria: In addition to above, the MESI form within 14 calendar 
days of the investigat or's first knowledge of the AE
Non-serious AE fulfilling the MESI criteria: The AE form, and SIFandMESI  form within 
14 calendar days of the investigator's first knowledge of the event
Non –serious AEs with additional data collection: The AE form and specific event form 
within 14 calendar days of the investigator’s first knowledge of the event
Events for adjud ication : Event Adjudication Document Col lection Form must be completed 
within [ADDRESS_664818] details (fax, phone, e - mail and address) are provided in the investigator trial master file.
An AE is 
obser ved and 
reported It is an SAE
complete :
AE form ≤ 24 hours
SIF ≤ 5 calendars days
It is a non-serious AE
complete :
AE form ≤ 14 calendar 
daysFulfilling 
seriousness 
criteria?
Addition al 
data 
collection 
requeried?Additional 
data 
collection 
required?Comp lete ≤ 14 calendar days :
Specifi c event form
For medication  Error 
(MESI): Medication  Error 
form 
No ad ditional f orms to 
be comp letedYes
No
Comp lete ≤ 14 calendar days : 
Specifi c event form
For Medication Error 
(MESI):  SIF and 
Medication  Error formYesNoNoYes
Is th e AE 
categ ory selected 
for adjudication ?Comp lete ≤ 14 
calendar days :
Adjud ication 
form Yes
AE: Adverse Event
SIF: safety information form
All timelines ar e from the investigator’s
first knowledge of the even t
Addtiona l data collectiondescribed in chapter 8.4
Events for adjudic ation described in chapter  12.7No
Figure 12–1Initial reporting of AEs
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 55of [ADDRESS_664819]- related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and good clinical practice 
(GCP )1.In addition, the investigator will be informed of any  trial-related SAEs that may warrant a 
change in an y trial procedure.
In accordance with regulatory  requirements, Novo Nordisk will inform the regulatory  authorities, 
including EMA, of trial product -related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the 
IRBs/IECs of trial prod uct-related S[LOCATION_003]Rs in accordance with local requirement and GCP1, unless 
locally  this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication
If a SAE and/or MESI is considered to have a causal relationship with a Novo Nordisk marketed 
product us ed as concomitant medication in the trial, it is important that the suspected relationship is 
reported to Novo Nordisk, e.g. in the alternative aetiology  section on the SIF. Novo Nordisk may  
need to report this adverse event to relevant regulatory  authorities.
12.[ADDRESS_664820] be reported to Novo Nordisk according to the following:
SAEs: All SAEs must be followed until the out come of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of 
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed the 
follow -up period and is expected by  [CONTACT_36308]. The SAE follow -up informati on 
should only  include new (e.g. corrections or additional) information and must be reported 
within 24 hours of the investigator's first knowledge of the information. This is also the case for 
previously  non- serious AEs which subsequentl y become SAEs
Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the 
end of the follow -up period stated in the protocol, whichever comes first, a nd until all queries 
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may  be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Case s can be closed with the outcome 
of “recovering/resolving” when the subject has completed the follow -up period and is expected 
by [CONTACT_513455]: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 56of 95
Non-serious AE fulfilling the MESI criteria: Non-serious AE fulfilling the MESI  criteria must 
be followed as specified for non -serious AEs. Follow -up information on MESI s should only  
include new (e.g. corrections or additional) information and must be reported within 14 
calendar days of the investigator’s first knowledge of the information. This is al so the case for 
previously  reported non -serious AEs which subseq uently  fulfil the MESI criteria
The investigator must ensure that the worst case severit y and seriousness of an event is kept 
throughout the trial. A worsening of an unresolved AE must be repo rted as follow up with re -
assessment of severity  and/or seriousness of the event.
Queries or follow -up requests from Novo Nordisk must be responded to within [ADDRESS_664821].
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints 
All technical complaints on any  of the following products: 
IDegLira (100 units/mL  + 3.6 mg/mL ), 3 mL pre -filled PDS290 pen
Novo Nordisk needles for prefil ledpen
IGlar (100 units/mL ),3 mL  pre-filled Solostar®,
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.
Contact [CONTACT_8972] (fax, e- mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any  AEs, SAEs, and/or 
MESI .
Technical complaints must be reported on a separate technical complaint form. A technical 
complaint form for each batch or lot number or for each DUN must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint :
Technical complaint assessed as related to an SAE within 24 hours
All other technical complaints within [ADDRESS_664822] enter the information on the technical complaint form in the 
eCRF .
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 57of [ADDRESS_664823]. The shipment of the technical complaint sample should be done in 
accordance with the same conditions as for storage (see section 9).
12.[ADDRESS_664824](s).
The investigator must follow the pregnancy  until the pregnancy  outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy , pregnancy  outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy , and AEs in the foetus and 
newborn infant.
The following must be collected and reported b y the investigator to Novo Nordisk - electronicall y 
(e.g. in PDF format), or by [CONTACT_36310]:
1.Reporting of pregnancy information
Information about the pregnancy  and pregnancy  outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively . 
When the pregnancy  outcome is abnormal (i.e. congenital anomalies, foetal death including 
sponta neous abortion and/or any  anomalies of the foetus observed at gross examination or 
during autops y), and/or when a congenital anomaly  is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In a ddition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 58of [ADDRESS_664825] be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow -up information. 
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy  as well as in the foetus and 
newborn infant(s). The SAEs that must be reported i nclude abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
Paper AE form* within 14 calendar days of the investigator's first knowledge of the initial 
or follow -up in formation to the non -serious AE
SAEs: 
Paper AE form* within 24 hours of the investigat or's first knowledge of the SAE
Paper SIFwithin 5 calendar days of the investigator's first knowledge of the SAE
SAE follow -up information to the AE form and/or SIFwithin 24 hours of the 
investigator's first knowled ge of the follow -up informati on
*It must be clearl y stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant.
Any queries or follow -up requests from Novo Nordisk to non -serious AEs, SAEs and pregnancy  
forms must be responded to by [CONTACT_19452] [ADDRESS_664826].
12.5.2 Pregnancies in female partners of male subjects (only applicable for US)
Male subjects must be instructed to notify  the investigator if their female partner becomes pregnant 
during the trial, except in the screening period. At the last scheduled visit, male subjects must be 
asked if their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow -up on the 
pregnancy  outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male subject and assess, if the pregnancy  
outcome is normal or abnormal. 
When the pregnancy  outcome is normal this information is recorded in the subject's medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy  
outcome is abnormal (i.e. congenital anomalies, f oetal death including spontaneous abortion and/or 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 59of 95
any anomalies of the foetus observed at gross examination or during autopsy ), the following must 
be reported b y the investigator to Novo Nordisk electronicall y (e.g. in PDF format) or b y fax:
1.Reporting of pregnancy information
Information from the male subject has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy  outcome and 
health status of the infant until the age of one mont h) has to be reported on the Maternal Forms 
1A, 1B and 2, after an informed consent has been obtained from the female partner. 
Initial reporting and follow -up information must be reported within 14 calendar days of the 
investigator's first knowledge of in itial or follow -up information. 
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probabl y related to the father's trea tment with 
the trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father's treatment 
with the trial product(s). This includes an abnormal outcome - such as foetal death 
(including spontaneous abortion) and congenital anomalies (including those observed at 
gross ex amination or during autops y of the foetus)
Forms and timelines for reporting AEs:
Please see section 12.5.1 , point 2, “Forms and timelines for reporting AEs”.
Any queries or follow -up requests from Novo Nordisk to non -serious AEs, SAEs and pregnancy  
forms must be responded to by  [CONTACT_19452] [ADDRESS_664827].
12.6 Precautions and/or overdose
During treatment with insulin there is a risk of h ypogl ycaemia.
Symptoms of hy poglycaemia usually  occur suddenly  and may  include cold sweat, nervousness or 
tremor, anxious feelings, unusual tiredness, confusion, difficulty  in concentrating, excessive hunger, 
temporary  vision changes, headache, nausea and palpi[INVESTIGATOR_332]. Severe hy poglycaemia may  lead to 
unconsciousness and death in worse case . 
Hypoglycaemic epi[INVESTIGATOR_513407]. Attention should be given to the fact that the action profile of the insulin component in 
IDegLira is flat and of somewhat longer duration than currently  marketed long -acting insulin 
preparations. I t may  therefore take seve ral hours more before stable normal BG is achieved after a 
hypoglycaemic epi[INVESTIGATOR_513408]. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 60of [ADDRESS_664828] medical practice 
(e.g. 25 mL of 50% dextrose solution given intravenously , or 0.5 -1mg of glucagon given s.c. or 
intramuscularl y).
From clinical trials and marketed use of Victoza®overdoses up to 40 times the recommended 
maintenance dose (72 mg) have been reported. Events reported included severe nausea and severe 
vomiting. None of the reports included severe h ypogl ycaemia. All subjects recovered without 
complications.
When initiating treatment with IDegLira, the subject may  in some cases experience loss of 
fluids/dehy dration, due to vomiting, nausea or diarrhoea. It is important to avoid dehy dration by 
[CONTACT_513456] y of fluids. For further information see the IDegLira IB3or any  update hereof.
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk has an internal IDegLira safet y committee constituted to perform ongoing safet y 
surveillance. The IDegL ira safety  committee may  recommend unblinding of any  data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the 
blinding of the trial personnel.
12.7.2 Event adjudication comm ittee
An independent exter nal EAC is established to perform qualitative validation of selected AEs 
according to pre -defined diagnostic criteria. The validation is based on review of pre -defined 
clinical data related to the specific AE. The events are reviewed b y the EAC in a blinded manner.
The following AEs will be adjudicated in this trial: 
Fatal events
Cardiovascular events:
oAcut e coronary  syndrome
oCereb rovascular event
oHeart failure requiring hospi[INVESTIGATOR_063]
Pancreatitis
Neoplasms (all kinds of abnormal growth) excluding th yroid neoplasm
Thyroid dis ease (th yroid neoplasm and/or th yroid disease requiring th yroidectomy)
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date durin g the screening period. Event adjudication will not be performed for AEs in screening 
failures. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 61of [ADDRESS_664829], trial protocol or amendments.
The EAC will review translated copi[INVESTIGATOR_513409] (for example X -ray, ECGs, ultrasound images, discharge summaries, 
pathology  reports, and death certificates). The EAC can evaluate an event, not initially  reported as 
an AE fo r adjudication, to be adjudi cated. The investigator must provide medical documentation as 
soon as possible, once the request from Novo Nordisk or the Event Adjudication vendor is received.
AEs for adjudication must be reported according to section
 12.2 . In addition the specific 
adjudication form should be completed within 14 calendar days of the investigator's first
knowledge of the AE, and all relevant predefined documents provided according to instructions in 
the event adjudication site manual.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 62of [ADDRESS_664830] or an assessment has not been done and will not be available, or if the question is 
irrelevant (e.g. , is not applicable), the investigator must indicate this accor ding to the data entry  
instructions.
The following will be provided as paper CRFs:
Pregnancy  forms
In addition paper AE ,technical complaint forms and SIF will be provided. These must be used 
when access to the eCRF is revoked or if the eCRF is unavailable .
On the paper CRF forms the investigator must print legibl y, using a ballpoint pen. The investigator 
must ensure that all questions are answered, and th at no empty  data blocks exist. It must be ensured 
that no information is recorded outside the data bloc ks. If a test/assessment has not been done and 
will not be available, the investigator must indicate this by  [CONTACT_565] “ND” (not done) in the 
appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) the 
investigator must in dicate this by  [CONTACT_565] “NA” (not applicable) in the appropriate answer field. 
Further guidance can be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By  
[CONTACT_43790] y signing the case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms
Corrections to the eCRF data may be made by  [CONTACT_36322]’s delegated staff. 
An audit trai l will be maintained in the 
eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made b y the investigator’s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again b ythe investigator.
13.[ADDRESS_664831] ensure that data is recorded in the eCRF as soon as possible, preferabl y 
within 5 calendar days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and validation purposes. Queries will be generated on an on -going 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 63of [ADDRESS_664832]’s last visit at the site. I n addition, queries must be 
resolved imm ediatel y in order to ensure the planned lock of the database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 64of [ADDRESS_664833] monitoring visit will be performed as soon as possible aft er FSFV at 
the trial site and no later than 6 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the CRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but w ill not exceed [ADDRESS_664834] access to source documents (original documents, data and 
records). Direct access includes permission to examine, anal yse, verify  and reproduce an y record(s) 
and report(s) that are important to the e valuation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. I n addition the relevant trial site staff should be available for discussions at monito ring 
visits and between monitoring visits ( e.g.by [CONTACT_648]). All data must be verifiable in source 
documentation other than the CRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any  time for any  data element.
The investigator is required to make a reasonable effort to obtain necessary additional information 
from external sources e.g. primary  physician and other hospi[INVESTIGATOR_600]/departments to document the 
subject s’ eligibility .
For SMPG measurements
;only the values entered in the diary  should be monitored as source data, 
although the BG meter can log a number of SMPG readings.
Source data g enerated b y the trial site can be corrected b y another person than the pe rson entering 
the source data if accepted by [CONTACT_427]; any  correction must be explained, signed and dated 
by [CONTACT_36324]. The original diaries and questionnaires must be collected b y 
the trial site and not be removed from the t rial site.
The monitor will ensure that the CRFs are completed and that paper CRFs are collected. The
following data will be source data verified for screening failures: 
Date for obtaining informed consent
Screen failure reason
Monitors must review the su bject's medical records and other source data (e.g., the diaries and 
questionnaires) to ensure consistency  and/or identify  omissions compared to the CRF. If 
discrepancies are found, the investigator must be questioned about these.
A follow -up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any  action to be taken.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 65of [ADDRESS_664835] Operating Procedures and I T architecture documentation. The use and 
control of these s ystems are documented.
Investigators working on the trial may  use their own electronic s ystems to capture source data. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 66of 95
17Statistical considerations
Novo Nordisk will anal yse and report data from all sites together.
All analy ses of efficacy  and safet y endpoints will be based on th e full analy sis set (FAS). 
All efficacy  endpoints and PRO endpoints will be summarised using the FAS and safet y endpoints 
will be summarised using the safet y anal ysis set (SAS).
The impact of protocol deviations and outliers may  be investigated further in sensitivity  anal yses if 
deemed relevant.
Unless otherwise specified, all continuous measurements will be summarised descriptivel y at each 
visit by  [CONTACT_513457]. Endpoints that are anal ysed untransformed and endpoints 
that are not formally analy sed are summarised by  [CONTACT_513458], standard deviation , median, 
and minimum and maximum value. Endpoints that are anal ysed log -transformed are supplemented 
with the geometric mean and coefficient of variation. For measurements over time, mean values 
will be plotted to explore the trajectory  over time. Observed data will be used as the basis for 
plotting data if not otherwise specified. Change from baseline plots will be based on Least Square 
Means and SEs estimated from the mixed model for repe ated measurement (MMRM). For 
endpoints that are anal ysed log -transformed, the geometric mean values will be plotted. I n addition, 
plots will be made showing mean curves b y time of treatment discontinuation. All descriptive 
summaries and plots will be based on on-treatment data unless otherwise specified.
Only  endpoints derived after 26 and 104 weeks of treatment will be anal ysed statistically . 
Subjects withdrawing from the trial or discontinuing treatment will contribute to the primary  
analysis as needing rescue therap y from the time of withdrawal/discontinuation. 
For secondary  endpoints, the expected percentage of missing data after 26 weeks of treatment is 
around 5%. Due to the nature of the trial design, the expected percentage of missing data after 104
weeks of treatment is 40% and 60% for IDegL ira and IGlar respectivel y. 
If an assessment has been made both at screening and randomisation, and if not otherwise specified, 
the value from the randomisation visit will be used as the baseline value. If the v alue measured at 
the randomisation visit is missing and the assessment also has been made at screening, then the 
screening value will be used as the baseline value.
Laboratory  values below the lower limit of quantification (LLOQ) will be set to ½LLOQ.
A MM RM with an unstructured covariance matrix, with testing performed at week 26 and 104 will 
be applied for secondary  continuous endpoints. The model includes treatment, visit, HbA 1cgroup, 
pre-
trial diabetes medication and region as fixed factors and the cor responding baseline value as a 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 67of 95
covariate. Interactions between visit and all factors and the covariate are also to be included in the 
model. 
The factor “baseline HbA 1c group” is a dichotomised baseline HbA 1cvariable with 2 categories: 
HbA 1c<8.5% or HbA 1c≥8.5%.
The factor “previous OAD treatment” has 2levels: OAD(s) + sulphon ylurea or OAD(s).
The factor “region” has 5 levels: Europe (Norway , Israel, Russia, Turkey , Italy , [LOCATION_006], Slovakia, 
Hungary , Czech Republic and Poland), North America (US), South Ameri ca (Mexico, Brazil and 
Argentina), Africa (South Africa), and Asia (India).
In the following, this model will be referred to as the standard MMRM model. This anal ysis will 
estimate the difference in change from baseline in the endpoint between IDegLira and I Glar 
assuming that subjects remain on tria l product until week [ADDRESS_664836] missing 
data will arise from subjects withdrawing due to inadequate glucose control as observed at the time 
of withdrawal. 
Presentation of results from a statistical analy sis will include the estimated mean treatment effects 
(Least Square Mean s) for absolute values and change from baseline. In addition, estimated mean 
treatment difference (or ratio) will be presented together with the two -
sided 95% confidence 
interval and corresponding two -sided p -value.
17.1 Sample size calculation
The primary  obje ctive of this trial is to compare long- term gly caemic control of IDegLira vs. IGlar 
in insulin naïve subjects with T2DM inadequatel y controlled with OAD(s). This is established by  
[CONTACT_513459] a stratified log -rank test. 
Formall y, let D be the hazard ratio for time to treatment intensification. The null -hypothesis of no 
treatment difference will be tested against the alternative hy pothesis as given by
H0: D =[ADDRESS_664837] HA: D ≠1
The need for treatment intensification is determined as the HbA 1c≥7% at 2consecutive visits from 
week 26 (including week 26, if HbA 1cwas ≥ 7% at week 12). Subjects withdrawing from the trial 
or discontinuing treatment will contribute to the primary  anal ysis as needing rescue therapy  from 
the time of withdrawal/discontinuation. The data will inherently  be interval censored, since HbA 1c
is only  measured at the scheduled visits while subjects may  reach an HbA 1c>7.0% at an y time 
between 2 visits. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 68of 95
The sample size is based on time from randomisation to the need of treatment intensification, a 1:1 
randomisation scheme, a 5% significance level and exponential survival.
Based on experience from the phase 3a development program f or IDegL ira and IDeg , it is assumed 
that around 45% in the IDegL ira arm will need treatment intensification compared with around 55% 
in the I Glar arm during the 2- year treatment period. Subjects withdrawing from the trial or 
discontinuing treatment are included in these p roportions as needing treatment intensification. Table 
17–1shows power calculations for vary ing effect sizes.
Table 17–1 Power for varying treatment differences
Percentage of subjects 
needing treatm ent 
intensification befor e end of 
trialIDegLira: 40%
IGlar: 55%
HR: 0.65IDegLira: 45%
IGlar: 55%
HR: 0.75 IDegLira: 50%
IGlar: 55%
HR: 0.86IDegLira: 55%
IGlar: 65%
HR: 0.72
800 subjects 99% 83% 31% 85%
1000 subjects >99% 90% 37% 92%
HR: hazard ratio
From these assumptions the sample size is set to 500 subjects per treatment arm; in total 
1000 subjects will be randomised. This will provide 90% power to detect a hazard ratio of 0.75 for 
IDegLira relative to IGlar (i.e., a 25% reduction in the risk of ne eding treatment intensification) 
using a two group log- rank test and a two -sided significance level of α = 0.05.
17.2 Definition of analysis sets
The following anal ysis sets are defined in acco rdance with the ICH -E9 guidance1:
Full Analysis Set (FAS): includes all randomised subjects. In exceptional cases, subjects may  be 
eliminated from the FAS. In such cases the elimination will be justified and documented.
The statistical evaluation of the FAS will fol low the intention -to-treat principle and subjects will 
contribute to the evaluation “ as randomised ”.
Safety Analysis Set (SAS): includes all subjects receiving at least [ADDRESS_664838] or comparator. Subjects in the safet y set will contribute to the evaluation “as treated ”.
Randomis ed subjects who are lost to follow up and where no exposure information of the
investigational product or comparators is available after randomisation will be handled as
unexposed.
Before data are released for statistical anal ysis, a review of all data wil l take place to identify  
protocol deviations that could potentially  affect the results. Any  decision to exclude any  subject or 
observation from the statistical analy sis is the joint responsibi lity of the members of the study
group. The subjects or observat ions to be excluded and the reason(s) for their exclusion will be 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 69of 95
documented and signed by [CONTACT_14381]. The documentation will be stored together with the remaining 
trial documentation.
17.3 Primary endpoint
The following endpoint will be assessed up to 104 we eks. T
ime from randomisation to inadequate 
glycaemic control and need for treatment intensification  defined as an HbA 1c  > 7% at 2 consecutive 
visits from week 26 (including week 26, if HbA 1c was > to 7% at week 12) .
Subjects withdrawing from the trial or discontinuing tr
eatment will contribute to the 
primary 
analysis as needing rescue therapy  from the time of withdrawal/discontinuation. The data will 
inherently
 be interval censored, since HbA 1c  is only measured at the scheduled visits while subjects 
may re ach an HbA 1c > 7.0% at an y time between  2 visits (including week 26 if HbA1c was > to 7% 
at week 12).
The primary endpoint will be anal ysed using a stratified log
-rank test where treatment, baseline 
HbA 1c
 group and previous OAD treatment will be included as strata in the model. 
The variable “baseline HbA 1c group” is a dichotomised baseline HbA 1c  variable with 2 categories: 
HbA 1c
 < 8.5% or HbA 1c  ≥ 8.5%.
The variable “previous OAD treatment” is a categoric al variable with 
2 categories: OAD(s) + 
sulphony lurea or OAD(s).
Formall y,
 let D be the hazard ratio for time to treatment intensification. The null -hypothesis of no 
treatm
ent difference will be tested against the alternative hy pothesis as given by
H0: D = [ADDRESS_664839] HA: D ≠[ADDRESS_664840] sensitivity analysis will take
 the interval censored nature of the data into account b y using 
a semi -parametric proportional hazards regression model for interval censored data. The chosen 
model can be viewed as an extension of Turnbull’s method24 from a non-p arametric model to a 
semi
-parametric proportional hazards models as described in Alioum .25
The log- likelihood function of the data under the proportional hazards  assumption can be expressed 
as:
Σi=1,...,n log (Σj=1,...,m μij(S(p j-1)exp(βzi)
 - S(p j)exp(βzi))),   
where :
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 70of 95
μij  is [ADDRESS_664841] i's observed interval encompass the jthTurnbull interval and 0 if this is not the
case
pj is the right endpoint of the jthTurnbull interval
zi is the covariate vector for subject i and β is the corresponding  vector of regression
coefficients
S is the survivor function for individuals with covariate vector zi = 0, based on the Turnbull
method, i.e. a survivor function whose positive mass is restricted to the Turnbull intervals but
which otherwise is free of constrictions (non -parametric)
Baseline HbA 1cgroup and previous OAD treatment will be included in the model by  [CONTACT_513460], 
i.e. when expressing the model with regards to the integrated hazard using the identity  -
log(S(t)exp(βz))= Λ(t,z) , we have Λ(t,z) =  Λ f (t)exp(βz) , where Λ f  is the integrated baseline hazard
for baseline HbA 1cand previous OAD treatment stratum f, f = (HbA 1c <8.5% and 
OAD(s), HbA 1c <
8.5% and OAD(s) + sulphony lurea , HbA 1c ≥8.5% and OAD(s), HbA 1c≥8.5% and OAD(s) +
sulphony lurea ), while treatm ent and region will be included as factors in the model.
The test of no difference between treatment groups will be performe d using a likelihood ratio test. 
In the second sensitivity  anal ysis the time to inadequate gly caemic control and need for treatment 
intensification will be compared 
between the IDegLira arm and the IGlar arm using a two -sided 
nonparametric test at a 5 % significance level. The test will be a generalised log rank test for inter val 
censored failure time data .26The analysis will not be based on an y model assumptions such as 
proportional hazards. The possible failure times will be consi dered as a discrete set of time points 
corresponding to the scheduled visits. An alternative but technicall y equivalent model would be to 
view the failure time as a continuous variable which can onl y be observed to lie in the interval 
between the visit whe n treatment failure is established and the previous scheduled visit.
17.4 Secondary endpoints
17.4.1 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
Time from randomisation to HbA 1c> 6.5% at 2 consecutive visits from week 26.
Time from randomisation to HbA 1c >6.5% at 2 consecutive visits from week 26 (including week 26 
if HbA 1cwas ˃6.5% at week 12). will be anal ysed and presented in the same way  as the primary  
endpoint .
HbA 1c
Change from baseline in HbA 1cafter [ADDRESS_664842] 
MMRM model.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 71of [ADDRESS_664843] MMRM model. 
Insulin dose after 26 and 104 weeks of treatment
The actual insulin dose will be summarised descri ptively  according to regimen as dose in units, and 
units/kg. The actual daily insulin dose will be analysed using the standard MMRM model.
HbA 1cresponder after 26 and 104 weeks of treatment (yes/no)
Two dichotomous endpoints (responder/non -responder) will be defined based on whether a subject 
has met a specific target level after 26 and 104 weeks of treatment:
HbA 1ctarget < 7.0 %7
HbA 1c target ≤ 6.5%27
Analy sis of each of the four responder endpoints will be based on a logistic regression model with 
treatment, HbA 1cgroup, previous OAD treatment and region as fixed factors and baseli ne HbA 1c
value as a covariate. Subjects withdrawing from the trial or discontinuing treatment will be imputed 
as being non-responder from time of withdrawal/discontinuation in line with the evaluation of the 
primary  endpoint.
HbA 1cresponder endpoints wit hout weight gain
Responder for HbA 1cwithout weight gain after 26 and 104 weeks of treatment will be defined as 
HbA 1c<7.0% or ≤6.5% and change in bod y weight from baseline ≤ 0. Analy sis of each of the 2
responder endpoints will be based on a logistic regression model with treatment, HbA 1cgroup, 
previous OAD treatment and region as fixed factors and baseline HbA 1cand baseline body  weight 
as covariates. Subjects withdrawing from the trial or discontinuin g treatment will be imputed as 
being non -responder from time of withdrawal/discontinuation in line with the evaluation of the 
primary  endpoint.
HbA 1cresponder end points without treatment -emergent severe or BG confirmed 
symptomatic hypoglycaemic epi[INVESTIGATOR_513410] 1c without treatment -emergent severe or BG confirmed sy mptomatic 
hypoglycaemic epi[INVESTIGATOR_11645] 26 and 104 weeks of treatment will be defined as HbA 1c< 7.0% or 
≤6.5% and without treatment -emergent severe or BG confirmed s ymptomatic hypogly caemic 
epi[INVESTIGATOR_513374] g the last 12 weeks of each treatment period. Anal ysis of each of the 2 responder 
endpoints will be based on a logistic regression model with treatment, HbA 1cgroup, previous OAD 
treatment and region as fixed factors and baseline HbA 1cvalues as a covariate. Subjects 
withdrawing from the trial or discontinuing treatment will be imputed as being non- responder from 
time of withdrawal/discontinuation in line with the evaluation of the primary  endpoint.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 72of 95
HbA 1crespon der endpoints without tr eatment- emergent severe or BG confirmed 
symptomatic hypoglycaemic epi[INVESTIGATOR_513411] 1c without treatment -emergent severe or BG confirmed sy mptomatic 
hypoglycaemic epi[INVESTIGATOR_513412] 26 and 104 weeks of tr eatment will be 
defined as HbA 1c<7.0% or ≤6.5% without treatment -emergent severe or BG confirmed 
symptomatic during the last 12 weeks of each treatment period, and change in body  weight from 
baseline ≤ 0 . Anal ysis of each of the 2 responder endpoints will be based on a logistic regression 
model with treatment, HbA 1cgroup, previous OAD treatment and region as fixed factors and 
baseline HbA 1c values and baseline bod y weight as covariates. Subjects withdrawing from the trial 
or discontinuing treatment will be imputed as being non- responder from time of 
withdrawal/discontinuation in line with the evaluation of the primary  endpoint.
Fasting plasma glucose
Change from baseline in FPG after [ADDRESS_664844] MMRM model. 
9-point profile
The following 6 endpoints from the 9 -point SMPG profile will be defined:
9-point profile (individual points in the profile)
Mean of the 9 -
point profile, defined as the area under the profile (calculated using the 
trapezoidal method) divided by  [CONTACT_36336]
Prandial plasma glucose increments (from before meal to [ADDRESS_664845], lunch and 
dinner). The mean increment over all meals will be derived as the mean of all available meal 
increments
AMMRM will be fitted to the 9-point profile data where measurements within subjects will be 
assumed correlated using an unstructured residual covariance matrix. The model will include 
treatment, visit, time, region and treatment b y time interaction as fixe d factors and baseline value 
corresponding to each time as covariate. Interactions between visit and all factors and covariates are 
also being included in the model. 
Change from baseline in mean of the [ADDRESS_664846] MMRM model. 
Blood pressure (systolic and diastolic)
Change from baseline in sy stolic and diastolic blood pressure will be anal ysed separatel y using the 
standard MMRM model. 
Fasting C -peptide and fasting hum an in sulin
These endpoints will be analy sed separatel y using the standard MMRM model. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 73of [ADDRESS_664847] MMRM model. I n these statistical analy ses, the 
endpoint will be log -transformed and so will the corresponding baseline covariate.
[IP_ADDRESS] Safety endpoints
Adverse events
AEs will be coded using the most recent version of the Medical Dictionary  for Regulatory  
Activities. 
A TEAE is defined as an event that has onset date on or after the 1stday of exposure to trial product
and no later than 7days after the last day  of trial product . If the event has onset date before the 1st
day of exposure on trial product and increases in severit y during the treatment period and until [ADDRESS_664848] 1event (N), the percentage of 
subjects with at least 1event (%), the number of events (E) and the eve nt rate per 100 years of 
exposure (R).
Summaries of TEAEs and of serious TEAEs will be presented as an overview including all AEs, 
serious AEs, number of deaths, AEs b y severity, AEs by [CONTACT_339710]. 
Furthermore summary  tables based on s ystem organ class and preferred terms are made for:
All TEAEs
Serious TEAEs
TEAEs possibly  or probably  related to trial product
Severe, moderate and mild TEAEs
TEAEs reported b y safety areas of interest
TEAEs with preferred term that are experienced by [CONTACT_2669] 5% (1%) of the subjects in any  
treatment arm or b y at least 5% (1%) of all subjects
A listing for non -TEAEs with onset date before the first day  of exposure to trial product will be 
presented. A listing will also be presented for non -TEAEs collected after the treatment-emergent 
period according to the definition of TEAE. All summaries will be prepared for TEAEs during [ADDRESS_664849] prematurely. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 74of [ADDRESS_664850] 1 event (N), the percentage of subjects with at least 1 event (%), the number of 
events (E) and the event rate per 100 years (R). 
Separate summaries are made b y severity considering all severe or BG confirmed symptomatic 
hypoglycaemic epi[INVESTIGATOR_1841], nocturnal severe or BG confirmed s ymptomatic hy poglycaemic epi[INVESTIGATOR_513413]. All summaries will be prepared for epi[INVESTIGATOR_51953] 
26 and 104 weeks of treatment separatel y.
A negative binomial model with a lo g-link function and the logarithm of the time period in which a 
hypoglycaemic epi[INVESTIGATOR_513414]- emergent as offset will be used to analyse the 
number of treatment- emergent severe or BG confirmed sy mptomatic hy pogly caemic epi[INVESTIGATOR_513380] 26 and 104 weeks of treatment. The model will further include treatment, HbA 1cgroup, 
previous OAD treatment and region as fixed factors.
Number of treatment -emergent nocturnal severe or BG confirmed s ymptomatic hy poglycaemic 
epi[INVESTIGATOR_51953] 26 and 104 weeks of treatment will be anal ysed using the same m odel as used for 
the treatment -emergent severe or BG confirmed sy mptomatic hy poglycaemic epi[INVESTIGATOR_1841].
Clinical evaluation (eye examination, ECG and urine albumin/creatinine ratio )
Eye examination ,ECG findings and urine albumin/creatinine ratio will be summarised 
descriptivel y, including:
Summaries for each visit
Change from baseline after [ADDRESS_664851] MMRM model.
Laboratory assessment s(Biochemistry, Haematology and Calcitonin)
All laboratory  parameters will be summarised descriptively .
The following tables will be presented:
Shift tables from baseline to after 26 and 104 weeks of treatment
Proportion of subjects with measurements outs ide reference range b y treatment and week
Laboratory  values will be presented graphically  as box plots by  [CONTACT_57485]. For each 
laboratory  parameter, individual values outside the reference ranges (abnormal values) will be 
listed. Summaries by  [CONTACT_513461]. If a blood re -
sample related to a specific visit is made, the first value will be used. 
Shift and outlier tabulations as well as listings will include all recorded values, including values 
from unscheduled visits
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 75of 95
For lipase and am ylase the following rule applies in the evaluation of the result :
If the am ylase or lipase baseline (at screening) value is > 3x upper normal range the information 
will be regarded as m edical history  for that subject
Clas sification of Hypoglycaemia
Treatment -emergent: hypoglycaemic epi[INVESTIGATOR_513415]
-emergent if the onset of 
the epi[INVESTIGATOR_513416], and no later than [ADDRESS_664852] .
Nocturnal h ypogl ycaemic epi[INVESTIGATOR_1841]: are epi[INVESTIGATOR_111378] 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_513417] (seeFigure 17–1) and the ADA classification of h ypogl ycaemia (see Figure 17–2).
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 76of 95
Novo Nordisk classification of hypoglycaemia
In normal ph ysiology , symptoms of hy pogly caemia occur below a plasma glucose level of 3.1 
mmol/L  (56 mg/dL).28Therefore, Novo Nordisk has included h ypoglycaemia with plasma glucose 
levels below this cut -off point in the definition of BG confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification: 
Severe h ypogl ycaemia according to the ADA classification29
Symptomatic BG confirmed hy poglycaemia: An epi[INVESTIGATOR_513418] < 3.1 mmol/ L (56 mg/dL) with symptoms consistent with hy poglycaemia
Severe or BG confirmed sy mptomatic hy pogly caemia: An epi[INVESTIGATOR_513419]29or BG confirmed b y a plasma glucose value < 3.1 mmol/L  (56 mg/dL)
with symptoms consistent with h ypoglycaemia
Hypog lycaemic
epi[INVESTIGATOR_156028] ≤ 3.9 mmol /L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizu re, coma or  
fatal 
SMPG
measurementPG < 3.1 mmol /L
(56 mg/dL)
with sympt oms
PG < 3.1 mmol /L
(56 mg/dL)
withou t
sympt omsSympt omatic  BG 
confirm ed 
hypoglycaemia
Asympto matic BG 
confirm ed 
hypoglycaemiaYesNo
Severe or 
BG con firmed  
symptomat ic 
hypoglycae mia
BG con firmed  
hypoglycae mia
Severe or BG 
confirm ed 
hypoglycaemia
Note: Glucose measurement s are per formed wi th capil lary blood calibrated to plasma equival ent glucose val ues
Subject 
able to 
treat him /
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–1  Novo Nordisk classification of hypoglycaemia 
ADA classification17 of hypoglycaemia
Severe h ypogl ycaemia: An epi[INVESTIGATOR_513420], glucagon, or take other corrective actions. Plasma glucose concentrations may  not
be available during an event, but neurological recovery  following the return of plasma glucose
to normal is considered sufficient evidence t hat the event was induced by  a low plasma glucose
concentration
Asymptomatic hy poglycaemia: An epi[INVESTIGATOR_513421] b y typi[INVESTIGATOR_2855] s ymptoms of
hypoglycaemia, but with a measured plasma glucose concentration ≤ 3.9 mmol/L  (70 mg/dL)
Documented s ymptomatic hy poglycaemia: An epi[INVESTIGATOR_513422] t ypi[INVESTIGATOR_513423]  a measured plasma glucose concentration ≤ 3.9 mmol/L  (70
mg/dL)
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 77of 95
Pseudo- hypoglycaemia: An epi[INVESTIGATOR_513424] y of the 
typi[INVESTIGATOR_2855] s ymptoms of hy poglycaemia with a measured plasma glucose concentration > 3.9 
mmol/L  (70 mg/dL) but approaching that level
Probable sy mptomatic hypogl ycaemia: An epi[INVESTIGATOR_513425] b y a plasma glucose determination but that was presumably  caused b y a 
plasma glucose concentration ≤ 3.9 mmol/L  (70 mg/dL)
Hypogl ycaemic 
epi[INVESTIGATOR_36249] ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
sympt omatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
sympt omatic 
hypoglycaemiaNo
Yes
No measurement 
withsymptomsPG > 3.9 mmol/L 
(70 mg/dL)
withsymptomsPG ≤ 3.9 mmol/L 
(70 mg/dL)
withsymptomsPG ≤ 3.9 mmol/L 
(70 mg/dL)
withoutsymptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_36250]/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–2 ADA classification of hypoglycaemia
17.5 Health economics endpoints
The following questionnaires will be used to compare PROs between treatments:
SF-36v221
TRIM
-D22
For each questionnaire, the summary  scores will be summarised descriptively  by [CONTACT_513462] y using the standard MMRM model. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 78of [ADDRESS_664853] and gradual dose adjustment. Furthermore, subjects are full y 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 79of [ADDRESS_664854] the investigator 
in cas e of an y concerns regarding the trial participation.
Clinical risk profile of IDegLira and r isk mitigations for NN9068 -4228
The following important potential and identified risks with I DegL ira are derived from completed 
trials with I DegLira as well as from the development programmes of its individual components, 
IDeg and liraglutide, and all of which will be closely  followed in this trial:
Identified risks
Hypoglycaemia
Hypoglycaemia is a pharmacological effect from insulin administration. The addition of l iraglutide 
to IDeg has shown to reduce the requirement of exogenous insulin and hence minimise the risk of 
hypoglycaemia.
Immu nogenicity (allergic reactions)
All peptide/protein based drugs have an inherent risk of allergic reactions. Allergic reactions ar e 
well known class effects for insulins and GLP-[ADDRESS_664855] s and pancreatitis has been suggested 
based on case reports received in clinical trials and during marketed use of drugs from this class. 
Even though a final conclusion regarding a causal relationship has not been established30a causal 
relationship is possible, and acute pancreatitis (acute or chronic) is therefore considered an 
identified risk for all GLP-[ADDRESS_664856] been few clinical reported events of acute pancreatitis (inflammation of the pancreas) 
presenting with persistent severe abdominal pain (usually  accompanied b y vomiting) with 
liraglutide treatment. As a consequence of the known events of acute pancreatitis, No vo Nordisk 
will analy se blood samples for am ylase and lipase during the trial to monitor the subjects’ safet y. 
Furthermore, participating subjects should be informed of the characteristic sy mptoms of acute 
pancreatitis. If pancreatitis is suspected, IDegLi ra and other potentiall y suspected medicinal 
products will be discont inued.
Gastrointestinal adverse events
Gastrointestinal adverse events are considered class effects for GLP -[ADDRESS_664857] frequently  reported events in patien ts treated with IDegLira. The gradual 
titration 
of IDegLira is slow and has previousl y shown to result in a lower frequency of gastrointestinal 
adverse effects. The dose of the liraglutide component in the start dose of IDegL ira in the present 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 80of 95
trial NN9068-4228 is 0.36 mg, which is less than the starting dose of liraglutide when administered 
as the mono component (Victoza®). 
Potential risks
Altered r enal function
Dehydration due to known gastrointestinal effects associated with GLP -
1receptor agonists may i n 
rare cases be associated with renal impairment in predisposed subjects. Subjects treated with 
IDegLira should be advised of the potential risk of dehy dration in relation to gastrointestinal side 
effects and take precautions to avoid fluid depletion. Furt hermore, impaired renal function as 
defined in the protocol is an exclusion criterion in this trial. Monitoring of creatinine will be 
performed during the trial as part of standard safety laboratory  surveillance.
Medullary thyroid cancer (C -Cell c arcinogen icity)
Thyroid C -cell carcinogenicity  has been reported in rats and mice treated with GL P-[ADDRESS_664858]
treatment wi ll be withdrawn in patients with suspi[INVESTIGATOR_1884]/diagnosed pancreatic cancer and 
appropri ate treatment and monitoring wi ll be initiated.
Epi[INVESTIGATOR_513426] T2DM are at significantly  highe r risk for man y 
forms of cancer .32,33
Cardiovascular d isorders
T2DM is associated with an increased risk of cardiovascular disease, which is a major diabetic 
complicat ion leading to death in this population. In the clinical development programme for 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 81of 95
liraglutide and IDegLira, a mean increase in pulse (by 2 -3 bpm) and a slight decrease in s ystolic 
blood pressure have been observed. The long- term clinical effects of the in crease in pulse have not 
been established. Therefore, cardiovascular disorders are recognised as an important potential risk 
for IDegL ira.
The following cardiovascular events will be followed closel y: acute coronary  syndrome, 
cerebrovascular event and hear t failure requiring hospi[INVESTIGATOR_063]. I n addition, selected 
cardiovascular events and all cause death will be adjudicated b y the EAC.
Lack of efficacy due to anti -IDeg or anti -liraglutide antibody formation
Consistent with the potentially  immunogenic pro perties of protein and peptide pharmaceuticals, 
subject s may develop anti -IDeg and anti -liraglutide antibodies following treatment with liraglutide 
and IDeg. Antibody  formation seems to be of no consequence for the efficacy and the safet y of 
liraglutide or current insulin preparations.
Medication errors, including errors with transfer from injectable diabetes therapy
Medication errors may  occur due to lack of training before initiating IDegLira therap y, subjects
unawareness of difference between IDegL ira and other injectable diabetes therapy  (insulin or GLP -
1 receptor agonists) or distraction during preparation for injection. Mixing up IDegLira with 
different t ypes of insulin may result in hypo -and/or hy pergl ycaemia. Mixing up IDegLira with a 
GLP-[ADDRESS_664859]. The development programme has not identified any risks associated with the use of 
IDegLira that are not already  known from IDeg or liraglutide; for further information please see 
section 3.1. The benefits are therefore concluded to outweigh the risks, and the proposed use of 
IDegLira in trial NN9068- 4228 is considered warranted.
Other
In reproduction and development toxicity  studies liraglutide has been shown to be teratogenic in 
rats a nd rabbits including reduced growth and major abnormalities at s ystemic exposures below 
human exposure at the maximum recommended human dose of 1.8 mg/day. The US Victoza®
Prescribing Information includes the Pregnancy  Category  C (US FDA Pharmaceutical Pre gnancy  
Categories: “Animal reproduction studies have shown an adverse effect on the foetus and there are 
no adequate and well -controlled studies in humans, but potential benefits may  warrant use of the 
drug in pregnant women despi[INVESTIGATOR_47853]”). Due to this pregnant women and women with the 
intention to become pregnant, are excluded from the trial.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 82of [ADDRESS_664860] 
liraglutide dose of 3 mg/kg/day . These fibrosarcomas were attributed to the high local concentration 
of drug near the injection site. The liraglutide concentration in the clinical formulation (6 mg/ml) is 
10-times higher than the concentration in the formulation used in the carcinogenicity  study  (0.6 
mg/ml). T he observed increase in skin sarcomas in high
-dose male mice is of unknown relevance 
for human safet y.
Areas of special interest with regards to safety of trial product are described in detail in the I Deg IB4
current version or an y updates hereof, the liraglutide local approved labelling current version or an y 
updates hereof and/or the IDegLira IB3current version or any  updates hereof.
It is concluded that the potential benefits from participating in the trial outweigh the potential risks. 
The safet y profile for the investigational medicina l products generated from the clinical and 
nonclinical development programme has not revealed any  safety  issues that would prohibit 
administration of those in accordance with the planned clinical trial.
18.[ADDRESS_664861] comply  with applicable 
regulatory  requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before an y trial-related activity , the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand.
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the subject ample ti me to come to a decision whether or not to 
participate in the trial. 
A voluntary , signed and personall y dated informed consent must be obtained from the subject 
before an y trial -related activity .
The responsibility  for seeking informed consent must remain with the investigator, but the 
investigator may  delegate the task to a medically  qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally  dated by  [CONTACT_135562] -related activity .
If information becomes available that may  be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information mu st be provided and a new informed consent mus t be obtained.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 83of [ADDRESS_664862] be obtained if: 
A female subject becomes pregnant during the trial, the male partner should be asked to sign a 
separate informed consent form (if abnormalit y is found in the foetus or new -born infant)
A male s ubject report that his female partner has become pregnant during the trial, the female 
partner should be asked to sign a separate informed consent form (onl y applic able for the US)
In addition, a ll subjects will be asked to sign a separate informed consent form in order to give 
permission to collect cardiovascular information in case the subject withdraws. The subject will be 
asked to sign this additional informed consent when entering the trial a nd the cardiovascular 
information will be collected at the time of the initial planned EOT.
18.[ADDRESS_664863]’s data will be handled 
as follows:
Data alread y collected and data collected at the end -of-trial visit will be retained by  [CONTACT_49753], entered into the database and used for the trial report.
Safety  events will be reported to Novo Nordisk and regulatory  authorities according to 
local/national requireme nts
If data is use d, it will alway s be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_664864] may  receive information provided to the site by  [CONTACT_3454], example of this may  be
a “thank you for your participation letter” after completion of the t rial.
All written information to subjects must be sent to I RB/IEC for approval/favourable opi[INVESTIGATOR_513427].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory  authority  may  decide to stop the trial, part of the trial 
or a trial site at an y time, but agreement on procedures to be followed must be obtained.
If a trial is suspended or prematurel y terminated, the investigator must inform the subjects promptly  
and ensure appropriate therap y and follow -up. The investigator and/or Novo Nordisk must also 
promptly  inform the regulatory  authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit -risk anal ysis changes, the new evaluation must be 
provided to the I RBs/IECs in case it has an impact on the planned follow -up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 84of [ADDRESS_664865] be documented and explained in a protocol deviation b y stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database. 
Documentation on protocol deviations must be kept in the investigator's trial master file and 
sponsor trial master file.
20Audits and inspections
Any aspect of the clinical trial may  be subject to audits conducted by  [CONTACT_49755] I RBs/IECs. Audits and inspections may  
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permi ssion to examine, anal yse, verify  and reproduce any  record(s) 
and report(s) that are relevant to the evaluation of the trial.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 85of [ADDRESS_664866] be available 
to Novo Nordisk:
Regulatory  approval and/or acknowledgement of notification as required
Approval/favourable opi[INVESTIGATOR_35269] I RBs/IECs clearly  identify ing the documents reviewed as 
follows: protocol, any  protocol amendments, subject information/informed consent form, any 
other written information to be provided to the subject and subject recruitment materials
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
Curricula vitae of investigator and sub -investigator(s) (curre nt, dated and signed -must include 
documented GCP training or a certificate)
Signed receipt of Investigator's Brochure orSum
mary  of Product Characteristics
Signed and dated Agreement on Protocol
Signed and dated Agreement on Protocol A mendment, if applic able
Contract, signed b y the investigator and/or appropriate parties on behalf of the investigator’s site 
and Novo Nordisk
Source document agreement
Central laboratory  certification and normal ranges
Insurance statement, if applicable
Financial disclosure form from investigator and sub -investigator(s)
Only  applicable for US trial sites: 
For US trial sites: verification under disclosures per Code of Federal Reg ulations (CFR) of 
Financial Conflict of Interest
For US trial sites: FDA form [ADDRESS_664867] be complet ed and signed b y the investigator at each site
FDA form 1572
For US sites:
Intended for US sites
Conducted under the IND
All US inve stigators, as described above, will sign FDA Form 1572
For sites outside the US:
Intended for participating sites outside of the US
Not conducted under the IND
All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 86of 95
By [CONTACT_12142], each investigator agrees to comply  fully with ICH GCP1, applicable 
regulatory  requirements and the Declaration of Helsinki .2
By [CONTACT_12142], each investigator also agrees to allow Novo Nordisk to make investigator's 
name [CONTACT_513477]  
[CONTACT_513463] r egulations.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 87of [ADDRESS_664868] of the trial at his/her site. If any  tasks are del egated, 
the investigator must maintain a log of appropriately  qualified persons to whom he/she has 
delegated specified trial-related duties. The investigator must ensure that there is adequate training 
for all staff participating in the conduct of the trial. I t is the investigator's responsibility  to supervise 
the conduct of the trial and to protect the rights, safet y, and well -being of the subjects.
A qualified ph ysician, who is an investigator or a sub -investigator for the trial, must be responsible 
for all trial -related medical decisions.
The investigator must ensure adequate supervision of the conduct of the trial at the trial site. 
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually  and collectively  permit evaluation of the conduct of a trial and the q uality  of the data
produced) in the investigator trialmaster file. The documents including the subject identification 
code list should be kept in a secure locked facilit y, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary  technical and organisational safet y measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent an y 
unauthorised access to data or an
y other processing of data against applicable law. T he investigator 
must be able to provide the necessary  information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safet y measures have been taken.
During an y period of unavailability , the investigator must del egate responsibility  for medical care of 
subjects to a specific qualified phy sician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator ( e.g.if he/she moves or retires), 
a new inve stigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site perso nnel must have sufficient English skills according to their 
assigned task(s).
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 88of [ADDRESS_664869], if deemed necessary  by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects study ing the same disease and/or trial product 
studied in this trial.
Novo Nordisk may  publish on its clinical trials website a redacted 
clinical trial report for this trial.
One investigator will be appointed by  [CONTACT_41170]
(signatory  investigator) on behalf of all participating investigators. The signatory  investigator will 
be appointed based upon the criteria defined b y the International Committee of Medical Journal 
Editors for research publications .[ADDRESS_664870] for 
Clinical Trial Disclosure .12
Novo Nordisk reserves the right to defer the release of data until specified milestones are reache d, 
for example when the clinical trial report is available. This includes the right not to release the 
results of interim anal yses, because the release of such information may  influence the results of the
entire trial.
At the end of the trial, oneor more scientific publications may  be prepared collaborativel y by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_664871] intellectual propert y.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 89of 95
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. I n the event of an y 
disagreement on the content of an y publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_49640] y and sufficiently represented in the publication.
Where required b y the journal, the investigator from each trial site will be na med in an 
acknowledgement or in the supplementary  material, as specified b y the journal. 
Novo Nordisk maintains the right to be informed of plans by  [CONTACT_513464] y scientific paper, presentation, communication or other infor mation concerning the 
investigation described in this protocol. Any  such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication. 
23.1.1 Authors hip
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors34(sometimes referred to as the Vancouver 
Criteria).
23.1.[ADDRESS_664872] their own research subjects' data .
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 90of [ADDRESS_664873]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper -
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy  any documents without prior permission 
from Novo Nordisk. If the inve stigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a s ystem in place to allow onl y 
the investigator to access the files.
The investigator must be able to access his/h er trial documents without involving Novo Nordisk in 
any way . Site -specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the sy stems and/or 
electronic devices supplied by  [CONTACT_3454]. These data must be retained by  [CONTACT_21655]. If the 
provided data ( e.g.the CD -ROM) is not readable during the entire storage period, the investigator 
can request a new cop y. A cop y of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 y ears. 
The files from the trial site/institution must be retained for 15 years after the completion of the trial, 
or longer if required b y local regulations or Novo Nordisk. In an y case trial files cannot be 
destroy ed until th e trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality  of data and must be done in accordance with local regulatory  requirements.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 91of 95
25Institutional Review Boards/Independent Ethics Committees and 
regulatory autho rities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/ IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk , as applicable, must promptly  report the 
following to the IRB/IEC, in accordance wit h local requirements: updates to I nvestigator's 
Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the sub jects, new information that may  affect adversel y the safety of the subjects or the 
conduct of the trial (including new benefit-risk analy sis in case it will have an impact on the 
planned follow -up of the subjects), annuall y written summaries of the trial s tatus, and other 
documents as required by  [CONTACT_1036]/IEC.
The investigator must ensure submission of the CTR synopsis to the I RB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_513428] r egulations, unles s necessary  to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records mus t be filed in the investigator trialmaster file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory  authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CTR according to national requirements.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 92of [ADDRESS_664874] liability  for its products, and liability  as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any  country , unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of n egligence, or any  other liability  of the sites or 
investigators conducting the trial, or b y persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts liability  in accordance with: 
Russia: Federal Law of 12 April 2010 No. 61-FZ "On Medicinal Drugs' Cerculation.
Polan d:Novo Nordisk carries liability  for the Study  exclusively  in the scope defined by  [CONTACT_513465] b y the Civil Code and the Pharmaceutical Law dated 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
support potential claims for liability  attributable to the Study , Novo Nordisk and Investigator are 
covered b y the Insurance Policy  issued according to applicable Polish law.
[LOCATION_008]: The company  sponsoring the research (the pharmaceutical compan y Novo 
Nordisk) carries product liability  for its products. If products from Novo Nordisk cause bodil y 
injury , legal liability  will usually  exist unless others have shown negligence. In the [LOCATION_006], 
compensation for an y injury  caused b y taking part in this study  will be in line with the guidelines of 
the Association of the British Pharmaceutical Industry  (ABPI). Broadl y speaking the ABPI 
[INVESTIGATOR_513429], Novo Nordisk, without legal commitment, should 
compensate you wit hout y ou having to prove that it is at fault. This applies in cases where it is 
likely  that an injury  results from giving a new drug or any  other procedure carried out in accordance 
with the protocol for the study . Novo Nordisk will not compensate you wher e injury  results from 
giving a new drug or an y other procedure in a manner which was not in accordance with the 
protocol for the stud y. Your right in law to claim compensation for injury where you can prove 
negligence is not affected. Copi[INVESTIGATOR_513430].
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 93of [ADDRESS_664875] amended b y the 64th WMA General Assembly, Fortaleza, Brazil. World Medical 
Association. 20 A.D.
3 Investigator´s Brochure, insulin degludec/liraglutide (7th edition). Novo Nordisk A/S. 2014.
4 Investigator's Broc hure, insulin degludec (10th Edition). Novo Nordisk A/S. 16 Dec 2014.
5 Lantus®-Summary  of Product Characteristics.  18 Jul 2014. 
6 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management 
of Hy pergl ycemia in Ty pe 2 Di abetes, 2015: A Patient- Centered Approach: Update to a 
Position Statement of the American Diabetes Association and the European Association for 
the Study  of Diabetes. Diabetes Care 2015; 38(1):140 -149.
7 American Diabetes Association. Standards of medica l care in diabetes. Diabetes Care 
2015;(38 (suppl.1):S1- S93).
[ADDRESS_664876] 2013; 19(2):[ADDRESS_664877] HW, L injawi S, Poulsen P et al. Efficacy  and safet y of a 
fixed -ratio combination of insulin degludec and liraglutide (IDegLira) compared with its 
components given alone: results of a phase 3, open- label, randomised, 26 -week, treat -to-target
trial in insulin -naive patients with ty pe 2 diabetes. L ancet Diabetes Endocrinol 2014; 
2(10):885-893.
[ADDRESS_664878] HW, L injawi S, Zacho M et al. One- year efficacy  and 
safet y of a fixed combination of insulin degludec and liraglut ide in patients with ty pe 2 
diabetes: results of a 26 -week extension to a 26 -week main trial. Diabetes Obes Metab 2015.
11 KDIGO. 2012 Clinical Practive Guideline for the Evaluation and Management of Chronic 
Kidney  Disease. Kidney  International Supplemen ts 2013; 3(1).
[ADDRESS_664879] for Clinical Trial Disclosure http:/novonordisk -
trial.com/website/content/how -we-disclose -trial-information.aspx. [ADDRESS_664880], 
Reporting, Editing and Publication of Scholarl y Work in Medical Journals. Dec 2014.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 94of [ADDRESS_664881] (FDAAA). 
2007.
15 The European Parliament and the Council of the European Council . Directive 2001/20/EC of 
the European Parliament and of the Councill of [ADDRESS_664882] of clinical trials on medicinal products 
for human use, article 11. Official Journal of the European Communities. May  2001.  1 May  
2001. 
16 The European Parliament and the Council of the European Council. Regulation (EC) No 
726/[ADDRESS_664883] ER, Anderson J, Childs B, Cry er P, Dagogo
-Jack S, Fish L et al. Hy pogly cemia and 
diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine 
Society . Diabetes Care 2013; 36(5):1384-1395.
18 McAulay  V, Deary  IJ, Frier BM. S ymptoms of hypogl ycaemia in people with diabetes. Diabet 
Med 2001; 18(9):690- 705.
19 U.S.Department of Health and Human Services, Food and Drug Administration. Guidance for 
Industry . Patient- Reported Outcome Measures: Use in Medical Product Development to 
Support L abeling Claims. 2009. 
http://www.fda.gov/downloads/Drugs/Guidedances/UCM193282.pdf
20 Stull DE, Leid y NK, Parasuraman B, Chassan y O. Optimal recall periods for patient- reported 
outcomes: challenges and potential solutions. Curr Med Res Opin 2009; 25(4):[ADDRESS_664884], RI , [LOCATION_003]: Qualit yMetric Icorporated; 
2007. Quality Metric Icorpora ted 2007.
[ADDRESS_664885] of treatment in diabetes: the Treatment -Related Impact Measures for Diabetes and 
Devices (TRIM -Diabetes and TRI M-Diabetes Device). Health Qual Life Outcomes 2009; 
7:83.
23 European Union. The rules governing medicinal products in the European Union, Volume 4, 
Annex 13, manufacture of investigational products - Brussels, Feb 2010.  
24 
Turnbull TW. The empi[INVESTIGATOR_513431], cencored and 
truncated data. Journal of the Roy al Statistical Society  1976; Series B 38:290-295.
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT no.: 2014 -005639 -15 Page: 95of 95
25 Alioum A, Commenges D. A proportional hazards model for arbitrarily  censored and 
truncated data. Biometrics 1996; 52(2):[ADDRESS_664886] for interval- censored failure time data with application to AI DS 
studies. Stat Med 1996; 15(13):1387-1395.
27 Garber AJ, Abrahamson MJ, Barzilay  JI, Blonde L, Bloomgarden ZT, Bush MA et al. 
American Association of Clinical Endocri nologists' comprehensive diabetes management 
algorithm [ADDRESS_664887] 2013; 19(3):536-557.
[ADDRESS_664888] 1987; 
79(3):777-781.
29 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes 
cars. 2014;37 (Suppl.1):23.  2014. 
30 Egan AG, Blind E, Dunder K, Graeff PA, H ummer BT, Bourcier T et al. Pancreatic Safet y of 
Incretin- based Drugs - FDA and EMA Assessment. New Engl J Med 2014; 370(9):794 -797.
31 Assessment report for GLP -1 based therapi[INVESTIGATOR_014], 25 July  2013 (EMA/474117/2013).  2013. 
32 Chodick G, Hey mann AD, Rosenmann L, Green MS, Flash S, Porath A et al. Diabetes and 
risk of incident cancer: a large population- based cohort study  in Israel. Cancer Causes Control 
2010; 21(6):879 -887.
33 Atchison EA, Gridley  G, Carreon JD, Leitzmann MF, McGl ynn KA. Risk of cancer i n a large 
cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128(3):635 -643.
34 International Committee of Medicinal Journal Editors. Uniform Requirements for Manuscripts 
submitted to Biomedical Journals. 336, 309 -315. 1997.  N Engl J Med. 
CONFIDENTIAL
Protocol -Appendix - A
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 1of [ADDRESS_664889], events with additional data 
collection and events requiring adjudication
Trial ID: NN9068-4228
DUALTMVIII–Durability
A 104 week clinical trial comparing long term glycaemic control of 
insulin degludec/liraglutide (IDegLira) versus insulin glargine 
therapy in subjects with type 2 diabetes mellitus
Trial phase : 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol -Appendix - A UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664890] No.: 2014 -005639 -15 Version: 1.0 Page: 2of 6
1Events with additional data collection and events r equiring adjudication 
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Fatal events All fatal events should be reported  including all -cause 
mortality: 
Cardiovascular death 
Non-cardiovascular death
Undetermined cause of deathAn FDA guidance document1requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type 2 
diabetes in order to ensure, that the new 
therapy does not increase the cardiovascular 
risk to an unacceptable extent.All events will be 
adjudicated
Acute coronary syndrome:
Myocardial 
infarction 
Hospi[INVESTIGATOR_513432] (MI) must be reported:
Spontaneous MI (including re -infarction and MI 
associated with stent thrombosis)
Percutaneous coronary intervention (PCI) related MI
Coronary artery by[CONTACT_10956] (CABG) related 
MI 
Silent MI
All events with symptoms of unstable angina requiring 
hospi[INVESTIGATOR_513433].AnFDA guidance document1requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type 2 
diabetes in order to ensure, that the new 
therapy does not increase the cardiovascular 
risk to an unacceptable extent.All events will be 
adjudicated
Cerebrovascular event 
(stroke or transient 
ischemic attack)Stroke (ischemic, haemorrhagic or undetermined) is 
defined as an acute epi[INVESTIGATOR_513434], 
caused by [CONTACT_513466], spi[INVESTIGATOR_1831], or retinal 
vascular injury.
Transient Ische mic Attack (TIA) is defined as a 
transient (<24 hours) epi[INVESTIGATOR_513435], spi[INVESTIGATOR_1831], or retinal ischemia, 
without acute infarction.An FDA guidance document1requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type 2 
diabetes in order to ensure, that the new 
therapy does not increase the cardiovascular 
risk to an unacceptable extent .All events will be 
adjudicated
CONFIDENTIAL
Protocol -Appendix - A UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664891] No.: 2014 -005639 -15 Version: 1.0 Page: 3of 6
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Heart failure requiring 
hospi[INVESTIGATOR_513436] a new epi[INVESTIGATOR_17114] w orsening of 
existing heart failure.An FDA guidance document1requests that 
Sponsors demonstrate the cardiovascular 
safety profile of any new therapy for type [ADDRESS_664892] a 
24 hour stay, will 
be adjudicated
Pancreatitis Two of the following three diagnostic criteria fulfilling 
the diagnosis of acute pancreatitis: 
Severe acute upper abdominal pain 
Elevated blood levels of pancreatic enzymes (lipase, 
amylase ) > 3xUNR
Characteristic imaging finding (ultrasound, 
computerised axial tomography (CT), magnetic 
resonance imaging (MRI))
Chronic pancreatitis will be defined by [CONTACT_513467] (ultrasound, CT, MRI) with abnormal 
pancreatic function tests or characteristic histological 
findings.Treatment with GLP -1 agonists has been 
associated with acute pancreatitis. Pancreatitis 
(including necrotising pancreatitis) is an 
identified risk according to the Company 
Core Data Sheet (CCDS) for liraglutide , a 
component of ID egLira. Novo Nordisk 
therefore monitors these events closely. All events will be 
adjudicated
CONFIDENTIAL
Protocol -Appendix - A UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664893] No.: 2014 -005639 -15 Version: 1.0 Page: 4of 6
Events with additional 
data collection and/or 
events requiring 
adjudication Definitions Rationale Event Adjudication 
Committee
Neoplasm All types of neoplasms (i.e. all new growth incl. polyps, 
warts etc.) must be reported including:
Malign neoplasm
In situ neoplasm
Benign neoplasm
Neoplasms of uncertain or unknown behaviour
(Please note: for operational reasons thyroid neoplasms 
will be reported as a thyroid disease and should not be 
reported as a Neoplasm)Neoplasm is an event we follow closely for 
GLP -1 analogues due to non -clinical findings 
in rats and mice treated with GLP -1 agonists.All neoplasm 
events, irrespective 
of malignancy 
stage ,will be 
adjudicated
Thyroid disease All disorders of thyroid gland (incl. thyroid neoplasms) 
must be reported.
Please refer to the protocol for further details on the 
assessments.Thyroid C -cells carcinogenicity has been 
reported in rats and mice treated w ith GLP -[ADDRESS_664894] ers 
which require 
thyroidectomy will 
be adjudicated
CONFIDENTIAL
Protocol -Appendix - A UTN: U1111 -1165 -3914 Date: 10 July 2015 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664895] No.: 2014 -005639 -15 Version: 1.0 Page: 5of [ADDRESS_664896] (MESI)
Medical Events of Special 
Interest Definitions Rationale Event Adjudication 
Committee
Medication errors 
concerning trial products1.Administration of wrong drug or use of w rong 
device. Note: Use of wrong DUN is not 
considered a medication error unless it results 
in administration of wrong drug. 
2.Wrong route of administration, such as 
intramuscular instead of subcutaneous
3.Administration of an overdose w ith th e 
intention to cause harm (e.g. suicide attempt)
4.Accidental administration of a low er or higher 
dose than intended . That is a dose low er or 
higher than 20% of the intended dose; 
however the administered dose must deviate 
from the int ended dose to an extent where 
clinical consequences for the trial subject 
were likely to happen as judged by [CONTACT_1275], although they did not necessarily 
occur.Standard MESI in all Novo Nordisk clinical 
trials.
Medication errors are captured to col lect 
information which may be used to improve 
the design, name [CONTACT_513478]/or information which may have an 
impact on product labelling (for example 
information about substantial overdoses).No adjudication
CONFIDENTIAL
Protocol -Appendix - A
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 6of 6
3Reference
1 Hicks KA, Hung HMJ, Mahaffey  KW, Mehran R, Nissen SE, Strockbridge NL et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Even ts in Clinical Trials 
(DRAFT). 20 Aug 2014.
CONFIDENTIAL
Protocol -Appendix B
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 1of 5
Appendix B
Monitoring of Calcitonin
Trial ID: NN9068-4228
DUALTMVIII –Durability
A 104 week clinical trial comparing long term glycaemic control 
of insulin degludec/liraglutide (IDegLira) versus insulin glargine 
therapy in subjects with type 2 diabetes mellitus
Trial phase : 3b
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may 
be disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to 
relevant parties
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol -Appendix B
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 2of 5
1Backgr ound
Treatment with GLP -1 receptor agonists has shown to be associated with thy roid C -cell changes in 
rodents but not in non- human primates. The human relevance of this finding is unknown. However, 
based on the findings in rodents, monitoring of serum calcitoni n (a sensitive biomarker for C- cell 
activation) is currently  being performed in clinical trials with insulin degludec/ liraglutide 
(IDegLira).
While there is general agreement on the clinical interpretation of substantially  elevated calcitonin 
levels (grea ter than 100 ng/L) as likely  indicative of C -cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively ) and 100 ng/L is 
less clear with regards to indication of disease. 
There are several kn own confounding factors affecting calcitonin levels, e.g.:
renal d ysfunction
smoking
autoimmune thy roiditis
several drug classes (e.g. proton pump inhibitors, beta
-blockers, H 2-blockers and 
glucocorticoids)
Physiology  of C -cell activation in various clini cal conditions and in different patient populations 
(i.e. with various co -morbidities) is poorly  understood. There may  be various clinical conditions not 
identified so far which mildly  or moderatel y affect calcitonin secretion by C -cells.
CONFIDENTIAL
Protocol -Appendix B
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 3of 5
2 Calcitonin monito ring
A blood sample will be drawn at pre -specified trial visits for measurement of calcitonin . Subjec ts 
with a calcitonin value 
≥ 50 ng/L cannot be randomised according to protocol section 6.3. In case 
a subject has a calcitonin value
 ≥ 10 ng/L the algorithm outlined in Figure 1 and described below 
should be followed. The algorithm applies for all calcitonin values including screening values.
Figure 1 Flow  of calcitonin monitoring
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject (even if a screen failure) must immediately be referred to a thy roid specialist 
for further evaluation and the trial product must be discontinued (see section 6.[ADDRESS_664897]). The subject can remain in the trial; however, all medications 
suspected to relate to this condition must be discontinued until diagnosis has been established. 
Background : These values were found in 9 (0.15%) of a population of 5817 patien ts with thy roid 
CONFIDENTIAL
Protocol -Appendix B
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 4of 5
nodular disease1. All of these patients were diagnosed with MTC resulting in a p ositive predictive 
value of 100%.
Diagnostic evaluation should include: 
thyroid ultrasound examination
fine needle aspi[INVESTIGATOR_36260] >1 cm 
potentially  surgery  with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the f amily  
history  of MTC or MEN2 and perform a genetic test for RET proto- oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject (even if a screen failure) should be referred to a th yroid specialist for further 
evaluation and the trial product should be discontinued. The subject can remain in the trial however; 
all medicat ions suspected to relate to this condition should be discontinued until appropriate 
treatment has been initiated. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thy roid 
nodular disease 1. Two of these subjec ts were diagnosed with MTC and two were diagnosed with C -
cell hy perplasia, resulting in a positive predictive value of a C- cell anomaly  of 50%.
Diagnostic evaluation should include: 
thyroid ultrasound examination 
if available no contraindication, a pentaga strin stimulation test. Subjects with positive 
pentagastrin stimulation tests should be considered to undergo surgery  
if pentagastrin is not available, thy roid ultrasound and fine needle aspi[INVESTIGATOR_513437] t he need for surgery .
2.3 Calcitonin ≥ 10 and <50 ng/L
Action: The subject can continue in the trial on trial product . Continue sampling of calcitonin 
according to the protocol. If the subject is a screen failure or if the value is from the last sample 
taken in the trial ,the subject should be referred to a thy roid specialist for further evaluation.
Background: Calcitonin values from 20 -50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thy roid nodular disease1. The predictive value of a C -cell anomaly  
for this calcitonin level was 8.3%. However, the likelihood of having a medullary  carcinoma > 1 cm 
with calcitonin in this range is extremel y low.
For calcitonin values 10 -20 ng/L Costante et al1identified 216 (3.7%) patients. One patient out of 
the 216 had a subsequent basal (unstimulated) calcitonin of 33 ng/L, and had C -cell h yperplasia at 
surgery . Two other studies used a cut
-off of CT > 10 ng/L to screen for C- cell disease, but they  do 
not provide sufficient information on patients with basal CT >10 and <20 ng/L to allow 
conclusions2
, 3.
CONFIDENTIAL
Protocol -Appendix B
CONFIDENTIALDate: 10 July 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 5of 5
3References
1 Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. 
Predictive value of serum calcitonin levels for preoperative diagnosis of medullary  thyroid 
carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 
2007; 92(2):450 -455.
2 Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmay er C et al. 
Sporadic h ypercalcitoninemia: clinical and therapeutic consequences. Endocrine- Related Cancer 
2009 2009; 16(1):243- 253.
3 Verga U, Ferrero S, Vicentini L , Brambilla T, Cirello V, Muzza M et al. 
Histopathological and molecular studies in patients with goiter and h ypercalcitoninemia: reactive or 
neoplastic C -cell h yperplasia? Endocr Relat Cancer 2007; 14(2):393 -403.
CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachment s I and II (if applicable) to the protocol arelocated in the Trial Master File.
Content: Global key  staff and Country  key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:IDegLira
Trial ID: NN9068-4228
Clinical Trial Report
Appendix 16.1.103 January 2019
0.1
Review
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 02 September 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 1of 5
Protocol Amendment
no 1
to Protocol, final version 1.0
dated 10July 2015
Trial ID:NN9068 -4228
DUALTMVIII – Durability
A 104 week clinical trial comparing long term glycaemic control
of insulin degludec/liraglutide (IDegLira) versus insulin glargine
therapy in subjects with type 2 diabetes mellitus
Trial phase: 3b
Applicable to Mexico
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment
CONFIDENTIALDate: 02 September 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 2of 5
Table of Contents    
Page
Table of Contents ..............................................................................................................................................2
1Introduction including rationale for the protocol amendment .............................................................3
2Changes ......................................................................................................................................................4
2.1   Changes in Section 3 Background information and rationale for the trial… ……..…..4
2.2   Changes in Section 6.5 Withdrawal Consent……………………………………………4
2.3   Changes in Section 26 Indemnity statement………………………………… ……… ….4
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 02 September 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 3of [ADDRESS_664898], and the compensation to which 
he/she will be entitled to in the event of suffering damages to his/her health directly attributable to 
the investigation, even in the event if he/she decides to withdraw or be withdrawn from such 
investigation. 
The foregoing is supported in Articles 100, 101, 102 section IV, of the General Health Law; 14 
sections I, VI, IX and X, 58 section III, 62 sections I , VIII and IX, and 115 of the Decree wherein 
there are amended, added and repealed several provisions contained in the Rulings of the General 
Health Law for Health Research Affairs; and numbers 4.6, 5.5, 5.7, 5 .10, 6.2, [IP_ADDRESS], 7.2, 10.8, 
11.1 and 11.2 of the NOM-012- SSA3 -2012 providing criteria for execution of projects for health 
research in human beings.
In this protocol amendment:
Any new text is written in italics.
Any text deleted from the protocol is wri tten using strike through .
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 02 September 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 4of 5
2Changes
2.1   Changes in Section 3 Background information and rationale for the trial
The following texts will be added to the protocol in page 15.
Mexico: 
In the case of Mexico the above will include the following responsibil ities for the head of the 
Institution/Health Care Establishment, Ethics, Research and, when applicable, Biosafety 
Committees and sponsor within their scope of responsibility: 
a)Investigation follow -up
b)Damages to health arising from the investigation develop ment; as well as those arising from
interruption or advanced suspension of treatment due to non -attributable reasons to the
Subject;
c)Timely compliance of the terms in which the authorization of a research for health in human
beings had been issued;
d)To pres ent in a timely manner the information required by [CONTACT_135534].
2.2   Changes in Section 6.5 Withdrawal Consent
The following text will be added to the protocol in page 26.
For Mexico: should the subject his/her family members parents or legal representative decide to 
withdraw the consent for participation in the trial, the subject will be entitled to receive 
appropriate, free of charge medical care and/or trial  drug during the follow up period of the 
protocol when it will be established with certainty that no untoward medical consequences of the 
subject´s participation in the research occurred.
2.3   Changes in Section 26 Indemnity statement
The following texts will be added to the protocol in page 92.
Novo Nordisk accept s liability  in accordance with:
Mexico: 
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 02 September 2015 Novo Nordisk
Trial ID: NN9068 -4228 Version: 1.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 5of 5
a) Novo Nordisk carries product liability for its products assumed under the special laws,
acts/and/or guidelines for conducting trials in any country, including those ap plicable
provisions on the Mexican [LOCATION_002].   If the subject feels that something goes wrong
during the course of this trial, the subject should contact [CONTACT_215592].
b) If during their participation in the trial the subject experiences a disease or injury that,
according to the trial doctor and the sponsor, is directly caused by [CONTACT_513468]/or a study procedure that otherwise would not have been part of his/her regular
medical care, the subject will receive from the Institution or Medical Care Establishment
and free of charge, the appropriate medical treatment as required. In this case, the costs
resulting from such treatment  as well as the costs of any indemnification established by [CONTACT_513469]; even if the  subject discontinues his/her participation in the study by [CONTACT_513470] a decision from the investigator.
c)By [CONTACT_79844], the subject will not renounce to any compensation or
indemnification he/she may be entitled to by [CONTACT_2371], nor will he/she will incur any additional
expense as a result of his/her participation in the trial; any additional expense resulting
from the subject’s participation in the trial   will be covered by [CONTACT_135568].
CONFIDENTIAL
Protocol Amendment 02 
Trial ID: NN9068-4228 
UTN: UI 111-1165-[ADDRESS_664899] No.: 2014-005639-15 Date: 
CONFIDENTIAL Version: 
Status: 
Page: 
Protocol Amendment 
no02 
to Protocol, final version 1. 0 
dated 10-Jul-2015 
Trial ID: NN9068-4228 18 December 2015 Novo Nordisk 
I 
Final 
I of6 
A 104 week clinical trial comparing long term glycaemic control of 
insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy 
in subjects with type 2 diabetes mellitus 
Trial phase: 3b 
Applicable to Norway 
Amendment originator: 
CONFIDENTIAL

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
CONFIDENTIAL
Protocol Amendment 02 
Trial ID: NN9068-4228 
UTN: Ul I l l-1165-[ADDRESS_664900] No.: 2014-005639-15 
Table of Contents CONFIDENTIALDate: 
Version: 
Status: 
Page: 18 December 2015 Novo Nordisk 
I 
Final 
3 of6 
Page 
Table of Contents .......................................................................................................... .................................... 3 
1 Introduction including rationale for the protocol amendment ............................................................. 4 
1.1 Rationale for the amendment ......................................................................................................... 4 
2 Changes ............................................. ............................ ............................................................................. 5 
2.1 Section 6.1 Number ofsubjects ..................................................................................................... 5 
2.2 Section 6.3 Exclusion criteria .................................................................................. ...................... 5 
2.3 Section 18.1 Benefit-risk assessment... .......................................................................................... 5 
3 References ..................... ........... ....................... ............ ............................. ............ .... 6 
CONFIDENTIAL
Protocol Amendment 02 
Trial ID: NN9068-4228 
UTN: U1111-1165-[ADDRESS_664901] No.: 2014-005639-15 CONFIDENTIAL Date: 
Version: 
Status: 
Page: 18 December 2015 Novo Nordisk 
I 
Final 
4 of6 
1 Introduction including rationale for the protocol amendment 
In this protocol amendment: 
•Any new text is written in italics.
•Any text deleted from the protocol is written using strike through.
1.1 Rationale for the amendment 
This amendment has been prepared in order to: 
1.Clarify number of subjects.
2.Revise exclusion criterion no. 3 in order to follow CTFG1 recommandations related to
contraception and pregnancy testing in clinical trials ( final version 2014-09-15).
3.Update risk benefit section with precautionary information about NYHA class III, inflammatory
bowel disease and diabetic gastroparesis
CONFIDENTIAL
Protocol Amendment 02 
Trial ID: NN9068-4228 CONFIDENTIAL Date: 
Version: 18 December 2015 Novo Nordisk 
I 
UTN: Ul 111-1165-[ADDRESS_664902] No.: 2014-005639-15 
2 Changes 
2.1 Section 6.1 Number of subjects Status: 
Page: 
Number of subjects planned to be screened: 1200 
Number of subjects planned to be randomised: 1000 
Mexico: 90 subjects are planned to be randomised/started on trial product in Mexico 
Number of subjects expected to complete the trial (on trial product): [ADDRESS_664903]-feeding or intend to become pregnant or of child-bearing
potential not using adequate highly effective contraceptive methods (highly effective adequate
contraceptive measures as required by [CONTACT_17993])
Norway: Highly effective methods are defined as established use of oral, injectable, transdermal, 
implantable or intravaginal hormonal methods of contraception associated with inhibition of 
ovulation, placement of an intrauterine device, female sterilisation, male sterilisation (where 
partner is sole partner of subject), or true abstinence (when in line with preferred and usual 
lifestyle). 
2.[ADDRESS_664904] 
only: Caution is advised when including patients with NYHA class Ill and the inclusion of patients 
with inflammatory bowel disease and diabetic gastroparesis is at the investigator's discretion. 
CONFIDENTIAL
Protocol Amendment 02 
Trial ID: NN9068-4228 
UTN: Ul l l l-1165-[ADDRESS_664905] No.: 2014-005639-15 
3 References CONFIDENTIAL Date: 
Version: 
Status: 
Page: 18 December 2015 Novo Nordisk 
1 
Final 
6 of6 
http:/ /www.hma.eu/fileadmin/dateien/Human Medicines/01-
About HMA/Working Groups/CTFG/2014 09 HMA CTFG Contraception.pdf 
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 1of 13
Protocol Amendment
no 3
to Protocol, final version 1.0
dated 10July 2015
Trial ID:
NN9068 -4228
DUALTMVIII – Durability
A 104 week clinical trial comparing long term gl ycaemic control of insulin degludec/liraglutide 
(IDegLira) versus insulin glargine therap y in subjects with type 2 diabetes mellitus
Trial phase: 3b
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
[ADDRESS_664906] be restricted to relevant 
parties.

Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 2of [ADDRESS_664907] ................................................................10 14
2.6 Section 6.4.1 Rescue criteria ........................................................................................................10 15
2.7 Section 8.1.3 Randomisation (visit 2) ..........................................................................................11 16
2.8 Section 8.1.4 Treatment initiation and titration ...........................................................................11 17
2.9 Section 8.4.1 Hypoglycaemic epi[INVESTIGATOR_1841] .......................................................................................11 18
2.10 Section 8.5 Laboratory assessments ............................................................................................12 19
2.11 Section 8.6 Other Assessments ....................................................................................................12 20
2.12 Section 9.4 Drug accountability and destruction .........................................................................12 21
2.13 Section 12.1 Definitions ..............................................................................................................12 22
23
Table of Figur es   24
Page 25
Figure 12–1 Initial reporting of AEs ...........................................................................................................13 26
27
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 3of 13
1 Intr oduction including rationale for  the protocol amendment 28
In this protocol amendment: 29
Any new text is written in italics. 30
Any text deleted from the protocol is written using strike through . 31
1.1 Rationale for the amendment 32
This amendment has been prepared in order to: 33
1.In Section 5.3, r emove the time constraint on the duration of OAD dose change s. The rationale 34
for this is that it may  be necessary  to change the dose of OAD(s) for longer than [ADDRESS_664908] should not be paused 43
while awaiting the confirmatory  FPG 44
5.Clarify  the rescue criteria in order to make it clear that they  apply  after baseline visit meaning 45
after initiation of treatment 46
6.In section 8.1.4 , align with previous and current DUAL protocols, that titration should be based 47
on the I nvestigators evaluation of the diary  taking hy po-, hypergl ycaemia etc. into consideration 48
7.Align wording in section 8.4.1 with the eCRF 49
8.Update that low FPG should be reported as Clinical Laboratory  Adverse Event (CLAE) at the [ADDRESS_664909] 
typographical error s 59
60
61
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 4of [ADDRESS_664910] of abbreviations 63
IRB/IEC Institutional Review Boards /Independent Ethics Committee s and regulatory 64
CONFIDENTIAL
Protocol Amendment UTN: U1111 -1165 -3914 Date: 28 June 2016 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664911] No.: 2014 -005639 -15 Version: 2.0 Page: 5of 13
2.2 Section 2 Flowchart 65
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664912]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_664913] RELATED
INFO/ASSESSMENTS
Informed consent X
In/exclusion criteria X X
Randomisation X
Pre-discontinuation of trial product X X X X X X X X X X X
Rescue criteria X X X X X
Withdraw al of consent X X X X X X X X X X X X X3X
Demography4X
Concomitant illness X
Medical history X
Diagnosis of diabetes X
Diabetes treatment history X
Diabetes complications X
Family history of diabetes X
                                                
1Subjects discontinuing trial product prematurely will be asked to attend the end of treatment visit and the 2follow up visits after discontinuation corresponding to V13, V14 and P15. After the 
follow up period the subject should have phone contacts scheduled every 3rdmonth (PX) until the additional premature discontinuation follow up (V13A) visit performed at week [ADDRESS_664914] prematurely 
4Collection of sex and date of birth, race and ethnicity only if applicable by [CONTACT_513471]: U1111 -1165 -3914 Date: 28 June 2016 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664915] No.: 2014 -005639 -15 Version: 2.0 Page: 6of 13
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664916]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Concomitant medication X X X X X X X X X X X X X X5X5 X6X6
Tobacco use (smoking status) X
EFFICACY
Glucose metabolism
Fasting plasma glucose X X X X X X X
HbA1c X X X X X X X X X X X
Fasting C -peptide X X X
Fasting human insulin X X X
Lipi[INVESTIGATOR_805] X X X X
Body m easurements
Height X
Body  weight7X X X X X X X X
BMI X
Self measured plasma glucose
QD8X X X X X X X X X X X X
9-point profile9X X X
SAFETY
                                                
5For subjects that have prematurely discontinued trial product only anti-diabetic medication will be collected
6Only concomitant medication with the indication diabetes will be collected 
7Body weight should be measured fasting except for V1
8Subjects should measure QD Self measured plasma glucose (SMPG) fasting prior t o breakfast.  Diabetes medication should be withheld until after the SMPG measurement
99-point profile should be measured within 1 week prior to the site visit (on a day where unusual strenuous exercise is not anti cipated)
CONFIDENTIAL
Protocol Amendment UTN: U1111 -1165 -3914 Date: 28 June 2016 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664917] No.: 2014 -005639 -15 Version: 2.0 Page: 7of 13
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664918]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
Adverse events X X X X X X X X X X X X X X X10X11X11
Hypoglycaemic epi[INVESTIGATOR_1841] X X X X X X X X X X X X X
Techn ical complaints X X X X X X X X X X X X
ECG X X12
Eye examination X13X14
Physical examination X X
Vital signs X X X X X X X
Bioch emistry15X X X X X
Haem atology16X X X X X
Hormo nes(calcitonin) X X X X X X X X X X
Urina lysis (albumin:creatinine ratio) X X X X X X
Pregn ancy test17X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) X
OTHER ASSESSMENTS
                                                
10Only AE information for potent ial major adverse cardiovascular events (MACE) will be collected
11Only AE information for potential major adverse cardiovascular events (MACE) and SAE information will be collected
12ECG obtained within [ADDRESS_664919] the screening assessment if res ults are available for evaluation at V2 
14Eye examination performed within 2 weeks prior to V13 is acceptable if results are available for evaluation at V13
15Amylase, lipase, ALAT, albumin, alkaline phosphatase, ASAT, bilirubin s total, calcium ionized ,creatinine, potassium and sodium
16Erythrocytes, haematocrit, haemoglobin, leucocytes, thrombocytes, differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
17For women of childbearing potential a bl ood sample pregnancy test ( serum hCG ) must be performed at V1 and V13. Additionally, a urine pregnancy test must be performed at site if 
pregnancy is suspected or if a menstrual period is missed. If the subject reports missing menstrual period at a phone contact , the subject will have to attend the site for an unscheduled visit 
as soon as possible to have a urine pregnancy test perf ormed. If positive ,a confirmatory serum hCG must be sent to the central laboratory. If required by [CONTACT_1769], pregnancy test may be 
performed regularly
CONFIDENTIAL
Protocol Amendment UTN: U1111 -1165 -3914 Date: 28 June 2016 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664920] No.: 2014 -005639 -15 Version: 2.0 Page: 8of 13
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664921]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_664922] in BG meter use X X X
Attend visit fasting X X X X X X X
Make appointment for eye 
examinationX
CONFIDENTIAL
Protocol Amendment UTN: U1111 -1165 -3914 Date: 28 June 2016 Status: Final Novo Nordisk
Trial ID: NN9068 -[ADDRESS_664923] No.: 2014 -005639 -15 Version: 2.0 Page: 9of 13
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664924]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±3
End of treatment X
Sign off Casebook X18X
End of trial (subject completion) X18 X
[ADDRESS_664925]
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 10of 13
2.3 Section 5.3 Treatment of subjects 67
The dose and frequency  of OAD(s) should not be changed during the trial except for safet y reasons. [ADDRESS_664926]’s medical [ADDRESS_664927] and in the electronic case report fo rm (eCRF) to verify  compliance. Dose change in OAD(s) 70
for a maximum duration of 14 day s is allowed for safet y reasons ba sed on the Investigator's [ADDRESS_664928]’s medical records and in the eCRF. 73
2.4 Section 6.2 Inclusion criteria 74
7. Stable daily dose(s) including any  of the following antidiabetic drug(s)/regimens within 90 day s 75
prior to the day  of screening: 76
Biguanides (metformin ≥ [ADDRESS_664929]) 78
Other OAD(s) allowed: sulph onylurea, glinides, pi[INVESTIGATOR_051], and DPP4 -inhibitors ( ≥ half [ADDRESS_664930]) [ADDRESS_664931] meets rescue criteria or if following applies: [ADDRESS_664932] been conducted and approp riate treatment should be 89
initiated 90
2.6 S ection 6.4.1 Rescue criteria 91
If the fasting SMPG values taken on 3 consecutive day s or if any  of the FPG samples anal ysed by 92
the central laboratory  exceed the limit of: 93
15.0 mmol/L  (270 mg/dL) from after baseline to week 6, 94
13.3 mmol/L  (240 mg/dL) from week 7 to week 12, 95
11.1 mmol/L  (200 mg/dL) from week [ADDRESS_664933]. 100
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 11of 13
2.7 Section 8.1.3 Randomisation (visit 2) 101
The randomisation visit (visit 2) must take place no more than [ADDRESS_664934]’s level of glycaemic control, is taken into consideration when [ADDRESS_664935] SMPG values, measured on the 115
day of the titration and the 2 previous day s. Titration should preferabl y be performed on the same 116
days of the week throughout the trial (E.g., Monday s and Thursday s). The dose adjustment willbe [ADDRESS_664936] should include the following information: 120
Start date and time of h ypogl ycaemic epi[INVESTIGATOR_1865] 121
The plasma glucose level before treating the epi[INVESTIGATOR_1865] (if available) and an y follow up 122
measurements 123
The lowest value measured during the h ypoglycaemic epi[INVESTIGATOR_513438] 124
plasma glucose value for the epi[INVESTIGATOR_1865], the remaining values will be kept as source data 125
Whether the epi[INVESTIGATOR_36202] (Yes/No) 126
A hy poglycaemic epi[INVESTIGATOR_513439] [ADDRESS_664937] experiences symptoms later during the epi[INVESTIGATOR_1865]. 128
Whether the subject was able to treat him/herself 129
If the severity  of a hy pogly caemic epi[INVESTIGATOR_513395], only  one hy pogly caemic epi[INVESTIGATOR_1865] [ADDRESS_664938] severe degree of h ypogl ycaemia. 131
Date, time and dose of last I DegL ira/IGlar administration prior to the epi[INVESTIGATOR_1865] 132
Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865] 133
Whether the epi[INVESTIGATOR_36206] i n relation to phy sical activity 134
Change in Worsening of any concomitant illness (pre -existing illness) 135
Any sign of fever or other acute disease 136
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 12of 13
Whether the subject was asleep when the epi[INVESTIGATOR_36206] [ADDRESS_664939] 138
2.10 Section 8.5 Laboratory assessments 139
Blood samples for efficacy 140
Glucose metabolism: HbA 1C, fasting plasma glucose, beta cell function (fasting C- peptide 141
and fasting human insulin). Note: Low FPG values reported b y central laboratory  should 142
NOT be reported as hy poglycaemic epi[INVESTIGATOR_1841]; however these should be reported as an AE 143
related to the procedure (e.g. a FPG result of 2.9 mmol/L  (52 mg/dL) should be reported as 144
‘low plasma glucose of 2.9 mmol/L  (52 mg/dL)’) A FPG result < 3.9 mmol/L (70mg/dL) 145
should not be reported as a hypoglycaemic epi[INVESTIGATOR_36189] a clinical laboratory adverse 146
event (CLAE) at the discretion of the investigator (see Section 12.1 ). [ADDRESS_664940] be 152
documented either on the documents and/or in the subject’s medical record. [ADDRESS_664941] (used/partly  used or unused 157
including empt y packaging material) can be stored at room temperature and must be stored [ADDRESS_664942] (used/partly  used or unused) are accounted for. [ADDRESS_664943] always be reporte d as an SAE using the important medical event 163
criterion if no other seriousness criteria are applicable: 164
Suspi[INVESTIGATOR_36225] 165
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 28 June 2016 Novo Nordisk
Trial ID: NN9068 -4228 Version: 2.0
UTN: U1111 -1165 -3914 Status: Final
EudraCT No.: 2014 -005639 -15 Page: 13of 13
Risk of liver injury defined as alanine amino transferase (AL AT) or aspartate aminotransferase 166
(ASAT) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology exists (Hy's 167
law). 168
Figure 1 2–1 Initial reporting of AEs 169
An AE is 
observed and 
reported It is an SAE
complete :
AE form ≤ 24 hours
SIF ≤  5 calendars d ays
It is a non-serious AE
complete :
AE form ≤ 14 calendar 
daysFulfilling 
seriousness 
criter ia?
Additional 
data 
collec tion 
requeried ?Additional 
data 
collection 
required ?Complete ≤ 14 calendar da ys:
Specific even t form
For medicat ion Error 
(MESI): Medicat ion Error 
form 
No additional  forms t o 
be completedYes
No
Complete ≤ 14 calendar da ys: 
Specific even t form
For Medi cation Error 
(MESI):  SIF and
Medicati on Error formYesNoNoYes
Is the AE 
categ ory selected  
for adjudication?Complete ≤ 14 
calendar d ays:
Adjudication
form Yes
AE: Adverse Even t
SIF: safety information form
All time lines are  from the investigator’s
first knowled ge of the ev ent
Addtional  data collectiondescribed in chapter 8.4
Events for ad judication described in chapter 12.7No
170
171
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 1of 8
Protocol Amendment
no 4
to Protocol, final version 3.0
dated 30 June 2016
Trial ID: NN9068 -4228
DUALTMVIII – Durability
A 104 week clinical trial comparing long term glycaemic control
of insulin degludec/liraglutide (IDegLira) versus insulin glargine
therapy in subjects with type 2 diabetes mellitus
Trial phase: 3b
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment
CONFIDENTIALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 2of 8
Table of Contents
Page
Table of Contents ..............................................................................................................................................2
1Introduction including rationale for t he protocol amendment .............................................................3
2Changes to the protocol ............................................................................................................................4
2.1 2 Flowchart ....................................................................................................................................4
2.2 8.1.5 Diaries ...................................................................................................................................5
2.3 8.5 Labo ratory assessments ...........................................................................................................6
2.3.1 Editorial change ...........................................................................................................6
2.3.2 Text moved from 8.1.5 Diaries and including new text on haematology and 
fasting human insulin ...................................................................................................6
2.4 12 .1 Definitions .............................................................................................................................7
2.5 18.1 Benefit -risk assessment of the trial ........................................................................................8
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 3of 8
1 Intr oduction including rationale for  the protocol amendment
NN9068 -4228 Protocol (Version 3.0, 30 June 2016) will be amended for the following reas ons:
1. The ‘(x)’ will be removed from the p regnancy  testing row for visits 2-12 in the flowcha rt in 
section 2 as this is believed to be the root cause of a high number protocol deviations causing 
extra pregnancy testing.
2.The s ection on laboratory  assessments on page 34 will be moved under section 8.5 L aboratory  
assessments to ensure all information on laboratory  procedures are in one section .
3. In section 8.5 Laboratory assessments, the following changes will be implemented:
The section removed from page 34 concerning laboratory assessments will be moved into 
section 8.5 Laboratory  assessments , it will be placed after the current text.
Asentence will be added to clarify  the storage of haematology slides in cases where there is 
an abnormalit y.
It will be specified that fasting human insulin is not distributed to sites in the laboratory  
reports. Fasting human insulin is analy sed in batches and results will not be reported to sites 
as they  have no clinical significance .
An editoria l  correction will be made to the CLAE text, as equal to sy mbol is missing from 
‘≤3.9 mmol /L (70mg/dL)’.
4. The definition of Major Adverse Cardiovascular Event (MACE) will be clarified in section 12.1 
to ensure it aligns with the FDA definition. 
5. T he core compan y safet y sheet for IDegLira has been updated. This means the minimum 
mandatory  safety  text has been updated for IDegLira and needs to be i ncluded in the protocol 
section 18
.1Benefit -risk assessment of the trial.
In this protocol amendment:
Any new text is written in 
italics.
Any text deleted from the protocol is written using strike through .
CONFIDENTIAL
Protocol Amendment UTN:U1111 -1165 -3914 Date: 15 December 2016 Status: Final Novo Nordisk
Trial ID:NN9068 -[ADDRESS_664944] No.:2014 -005639 -15 Version: 1.0 Page: 4of 8
2Changes to the protocol
2.1 2 Flowchart
Trial Periods Screening Rand. Treat ment EOT FU1 FU2 Pre-disc1
Visit number (V), Phone contact (P)2V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 P15 PX V13A
Timing of visit (weeks)≤ [ADDRESS_664945]
month104
Visit window  (days) ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 ±3 ±[ADDRESS_664946] RELATED
INFO/ASSESSMENTS
Eye examination X13X14
Physical examination X X
Vital signs X X X X X X X
Bioch emistry15X X X X X
Haem atology16X X X X X
Hormo nes(calcitonin) X X X X X X X X X X
Urina lysis (albumin:creatinine ratio) X X X X X X
Pregn ancy test17X (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) X
CONFIDENTIAL
Protocol Amendment
CONFIDENT IALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 5of 8
2.2 8.1.5 Diaries
Laboratory assessments
The laboratory  anal yses will be handled by  a central laboratory . Descriptions of assay  methods, 
laboratory  supplies and procedures for obtaining samples, handling, transportation and storage of 
biological samples and information regarding who will perform the assessments, will be described 
in a trial specific laboratory  manual, provided by  [CONTACT_2237]  (for central laboratory  
details, see Attachment I). 
Laboratory  samples not drawn on the day  of the actual visit should preferably  be drawn on anot her 
day within the visit window (flow chart section 2). For some of the samples drawn during the trial 
the subject must be fasting, see the flow chart section [ADDRESS_664947] operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. 
Brazil : All laboratory  results from Brazilian subjects must be provided to the investigator.
Laboratory results will be provided by [CONTACT_513451]. 
For laboratory  results outside the normal range the investigator must specify  an evaluation on the 
labora tory report. The evaluation must follow the categories:
Normal
Abnormal
Was the result clinically  significant? (Yes/No)
The investigator must review all laboratory  results for concomitant illnesses and AEs and report 
these according to this protocol (see s ection 8.2.1 and section 12). The review of laboratory  reports 
must be documented either on the documents and/or in the subject’s medical record. The laboratory  
report must be evaluated as soon as possible and signed and dated b y the investigator on the da y of 
evaluation. The signed report must be retained at the site as source documentation. 
The investigator should ensure that all laboratory  samples for the subject are shipped to the 
laboratory  immediatel y after the samples from visit 1 and visit 13 (or visit 13A for prematurel y 
discontinued subjects) have been collected.
CONFIDENTIAL
Protocol Amendment
CONFIDENT IALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 6of [ADDRESS_664948] at the 
completion of the clinical trial report (CTR).  
2.3 8.5 Laboratory assessments
2.3.1 Editorial change
Blood and urine samples will be collected in accordance with the flow chart (section 2) and
analysed by [CONTACT_513472]:
Blood samples for efficacy
Glucose metabolism: HbA 1C, fasting plas ma glucose, beta cell function (fasting C -peptide and 
fasting human insulin). Note: A FPG result ≤ 3.9 mmol/L  (70mg/dL) should not be reported as a 
hypoglycaemic epi[INVESTIGATOR_36189] a clinical laboratory adverse event (CLAE) at the discretion of the 
investigat or (see Section 12.1).
2.3.2 Text moved from 8.1 .5 Diaries and including new text on haematology and fasting 
human insulin
The laboratory analyses will be handled by a central laboratory. Descriptions of assay methods, 
laboratory supplies and procedures for obtaining samples, handling, transportation and storage of 
biological samples and information regarding who will perform the assessments, will be described 
in a trial specific laboratory manual, provided by [CONTACT_2237] (for central laboratory 
details, see Attachment I). 
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on anot her 
day within the visit window (flow chart section 2 ). For some of the samples drawn during the trial 
the subject must be fasting, see the flow chart section [ADDRESS_664949] operating procedures. Such data will not be transferred to the trial database, 
but abnormal values will be reported to the investigator. 
Brazil : All laboratory results from Brazilian subjects must be provided to the investigator.
Laboratory results (except fasting human insulin) will be provided by [CONTACT_513473]. For laboratory results outside the normal range the investigator 
must spec ify an evaluation on the laboratory report. The evaluation must follow the categories:
CONFIDENTIAL
Protocol Amendment
CONFIDENT IALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 7of 8
Normal
Abnormal
Was the result clinically significant? (Yes/No)
The investigator must review all laboratory results for concomitant illnesses and AEs and report 
these according to this protocol (see section 8.2.1 and section 12). The review of laboratory reports 
must be documented either on the documents and/or in the subject’s medical record. The laboratory 
report must be evaluated as soon as possible and signed and dated by [CONTACT_513474]. The signed report must be retained at the site as source documentation. 
The investigator should ensure that all laboratory samples for the subject are shipped to the 
laboratory immediately after the samples from visit 1 and visit 13 (or visit 13A for prematurely 
discontinued subjects) have been collected.
All samples will be d estroyed on an ongoing basis after the analysis or at the latest at the 
completion of the clinical trial report (CTR). However ,in case of abnormal haematology analysis 
test results, part of the sample may be kept for up to 2 years.
2.4 12 .1 Definitions
Major Adverse Cardiovascular Event
A Major Adverse Cardiovascular Event (MACE) is A ny cardiovascular AE which can be
categorised into the following groups will be evaluated as a potential Major Adverse 
Cardiovascular Event (MACE):
Cardiovascular Death
Myocardial Infarction
Hospi[INVESTIGATOR_329890]
Transient Ischemic Attack and Stroke
Heart Failure Event (requiring hospi[INVESTIGATOR_11956])
Cardiac procedures
oInterventional Cardiology
oPeripheral Vascular Intervention
oStent Thrombosis
A MACE is defined as:
Cardiovascular Death
Non-fatal Myocardial Infarction
Non-fatal Stroke
CONFIDENTIAL
Protocol Amendment
CONFIDENT IALDate: 15 December 2016 Novo Nordisk
Trial ID:NN9068 -4228 Version: 1.0
UTN:U1111 -1165 -3914 Status: Final
EudraCT No.:2014 -005639 -15 Page: 8of [ADDRESS_664950] frequently  reported events in patients treated with IDegLira. The gradual titration
of IDegLira is slow and has previousl y shown to result in a lower frequency of gastrointestinal 
adverse effects. The dose of the liraglutide component in the start dose of IDegL ira in the present
trial NN9068-4228 is 0.36 mg, which is less than the starting dose of liraglutide when administered
as the mono component (Victoza®).
Gallstone disease
Cases of gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis) have been 
reported from clinical trials with IDegLira. Both cholelithiasis and cholecystitis have possible 
clinical implications for the patients as the events might lead to hospi[INVESTIGATOR_513440]. If cholelithiasis is suspected, treatment should be discontinued and gallbladder 
examination and appropriate clinical follow -up should be initiated. If acute  gallstone disease is 
confirmed, the trial product must be permanently discontinued.
CONFIDENTIAL